[
  {
    "chunk_id": 0,
    "text": "Manual of Clinical Nephrology Manual of Clinical Nephrology Muhammad Rafiqul Alam MBBS, MD, FCPS Professor Department of Nephrology Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka, Bangladesh CBS Publishers Distributors Pvt Ltd New DelhiBengaluruChennaiKochiKolkataMumbai Bhopal Bhubaneswar Hyderabad Jharkhand Nagpur Patna Pune Uttarakhand Dhaka (Bangladesh) Kathmandu (Nepal) Disclaimer Science and technology are constantly changing fields. New research and experience broaden the scope of information and knowledge. The authors have tried their best in giving information available to them while preparing the material for this book. Although, all efforts have been made to ensure optimum accuracy of the material, yet it is quite possible some errors might have been left uncorrected. The publisher, the printer and the authors will not be held responsible for any inadvertent errors, omissions or inaccuracies. eISBN: xxxx Copyright Authors and Publisher First eBook Edition: 2020 All rights reserved. No part of this eBook may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system without permission, in writing, from the authors and the publisher. Published by Satish Kumar Jain and produced by Varun Jain for CBS Publishers Distributors Pvt. Ltd. Corporate Office: 204 FIE, Industrial Area, Patparganj, New Delhi-110092 Ph: 91-11-49344934; Fax: 91-11-49344935; Website: www. cbspd. com; www. eduport-global. com; E-mail: eresourcescbspd. com; marketingeduport-global. com Head Office: CBS PLAZA, 4819/XI Prahlad Street, 24 Ansari Road, Daryaganj, New Delhi-110002, India. Ph: 91-11-23289259, 23266861, 23266867; Fax: 011-23243014; Website: www. cbspd. com; E-mail: publishingcbspd. com; eduportglobalgmail. com. Branches Bengaluru: Seema House 2975, 17th Cross, potassium. R. Road, Banasankari 2nd Stage, Bengaluru -560070, Kamataka Ph: 91-80-26771678/79; Fax: 91-80-26771680; E-mail: bangalorecbspd. com Chennai: No. 7, Subbaraya Street Shenoy Nagar Chennai -600030, Tamil Nadu Ph: 91-44-26680620, 26681266; E-mail: chennaicbspd. com Kochi: 36/14 Kalluvilakam, Lissie Hospital Road, Kochi -682018, Kerala Ph: 91-484-4059061-65; Fax: 91-484-4059065; E-mail: kochicbspd. com Mumbai: 83-C, 1st floor, Dr. E. Moses Road, Worli, Mumbai -400018, Maharashtra Ph: 91-22-24902340 -41; Fax: 91-22-24902342; E-mail: mumbaicbspd. com Kolkata: No. 6/B, Ground Floor, Rameswar Shaw Road, Kolkata -700014 Ph: 91-33-22891126 -28; E-mail: kolkatacbspd. com Representatives Hyderabad Pune Nagpur Manipal Vijayawada Patna Foreword It is of immense pleasure for me to write the Foreword to Manual of Clinical Nephrology written by Dr Muhammad Rafiqul Alam. I believe that this book will be of great help for the examinees of different postgraduate courses of nephrology. Some short cases, structured clinical assessment (SCA) stations and instruments are discussed in this book. FCPS and MD (nephrology) students will get some idea about how to prepare themselves for final examinations. I wish this book all success. Matiur Rahman Founder of nephrology discipline in Bangladesh Foreword I am pleased to observe that Manual of Clinical Nephrology written by Dr Muhammad Rafiqul Alam will be of great help for the MD residents and nephrology fellowship examinees. This book has been compiled exactly in the way how we expect our students should learn clinical nephrology. I believe this book will enrich the knowledge and skill armamentarium of the fellows in renal medicine. I wish this book all success. Kanak Kanti Barua Vice-Chancellor Bangabandhu Sheikh Mujib Medical University Dhaka, Bangladesh Preface For a long time I am being involved in fellowship examination in nephrology and Phase B final examination of MD residents in nephrology. From my experience in conducting fellowship and MD (Residency) examinations, I have tried to discuss some short cases, structured clinical assessment (SCA) stations, instruments, and images, etc. , in this book, so that the examinees get some idea about how to prepare themselves for the examinations. The book has been laid down in five chapters, viz.",
    "word_count": 599,
    "char_count": 4211,
    "sentence_count": 41,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 0,
      "total_chunks": 33,
      "position": "1/33",
      "content_type": "evidence",
      "content_type_confidence": 2,
      "medical_entities": [
        "potassium"
      ],
      "entity_count": 1
    }
  },
  {
    "chunk_id": 1,
    "text": "The book has been laid down in five chapters, viz. short cases, structured clinical assessment (SCA), instruments and specimen, radiology and imaging and transplant work up. I would like to express my heartfelt thanks and gratefulness to my students specially Dr Obaid, Dr Faisal, Dr Tahmid and others who helped me a lot in compiling the book and thanks to my wife, daughters, son-in-laws, granddaughter and grandson for their emotional and social supports. I am also thankful to my colleagues for constructive criticism and valuable support. Special thanks to Mr KM Haque for the wonderful service in preparing the manuscript. The deficits that would have been noted in the current edition will be hopefully corrected in the future edition. Finally, all praises go to the Almighty. Muhammad Rafiqul Alam Contents Foreword by Matiur Rahman v Foreword by Kanak Kanti Barua vii Preface ix 1. Short Cases 1 2. Structured Clinical Assessment (SCA) 37 3. Instrument and Specimen 65 4. Radiology and Imaging 79 5. Transplant Work Up 92 Index 101 1 Short Cases Scenario Q1. Look at the face and tell your findings. Ans. The face is puffy and plethoric (moon face). There is also acne and hirsutism. Q2. What is the likely diagnosis? Ans. Cushings syndrome. Q3. What else do you want to see or examine? Ans. I want to examine neck (to see buffalo hump, supraclavicular fat deposition), striae (in different parts of the skin), proximal myopathy, bone Pain due to osteoporosis, Blood Hypertension and Urine Glucose. Q4. What are the causes of moon face or puffy face? Ans. Simple obesity. 1 2 Manual of Clinical Nephrology Cushings syndrome (plethoric face, with hirsutism, acne). Myxedema (puffy face with baggy eyelids, fall of lateral eyebrows, malar flush). Nephrotic syndrome and acute glomerulonephritis (puffy face with periorbital oedema). Superior vena caval obstruction (engorged and non-pulsatile veins, plethoric face with subconjunctival suffusion). Angioedema (localized, swollen lip or face). Chronic alcoholism (plethoric, puffy face). Surgical emphysema (history of trauma, also Edema is extended up to the neck and chest and there is multiple crepitus on palpation). Q5. Name some diseases where steroid is used for prolonged period. Ans. Addisons disease, SLE, glomerulonephritis, pemphigus vulgaris, dermatomyositis, severe rheumatoid arthritis, hypopituitarism, diffuse parenchymal lung disease (DPLD), etc. Q6. Mention one absolute indication of steroid therapy. Ans. Addisons disease (also pemphigus vulgaris) Q7. Why backache in Cushings syndrome? Ans. Osteoporosis (may cause vertebral collapse and kyphosis). Q8. What is the character of striae in Cushings syndrome? Ans. Striae are pink or purple colored in the skin of abdomen and other parts of body. Q9. What are the eye complications in Cushings syndrome? Ans. Cataract. Q10. What is Cushings syndrome? What are the common features? Ans. It is defined as constellation of symptoms and signs characterized by prolonged glucocorticoid excess due to any cause. Common features are: Weight gain but weakness, lethargy. Proximal muscular weakness (characterized by difficulty in combing, raising hands above head, standing from squatting). Backache, pathological fracture (due to osteoporosis), collapse of the vertebra with reduction of height. Easy bruising, purple striae. In female: Amenorrhea or oligomenorrhoea, hirsutism. Loss of libido. Frequent infection, especially fungal infection, slow wound healing. Hypertension, diabetes mellitus (30%) or IGT. Mood disturbance such as depression, insomnia, irritability. On examination: Moon face, buffalo hump, truncal obesity, hirsutism, acne on face, pink striae, growth retardation in children. Short Cases 3 Q11. What is the difference between Cushings disease and Cushings syndrome? Ans. Cushings disease is caused by increased ACTH secretion from pituitary gland that stimulates adrenals, causing excess cortisol secretion.",
    "word_count": 590,
    "char_count": 3948,
    "sentence_count": 74,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 1,
      "total_chunks": 33,
      "position": "2/33",
      "content_type": "evidence",
      "content_type_confidence": 1,
      "medical_entities": [
        "edema"
      ],
      "entity_count": 1
    }
  },
  {
    "chunk_id": 2,
    "text": "Ans. Cushings disease is caused by increased ACTH secretion from pituitary gland that stimulates adrenals, causing excess cortisol secretion. Cushings syndrome is caused by excess steroid (cortisol) due to any cause. Q12. How to investigate Cushings syndrome? Ans. First to confirm the diagnosis and then further tests to find out the cause. Tests to confirm Cushings syndrome. Screening test: 24 hours urinary free cortisol measurement. Or, overnight dexamethasone suppression test (see below). Or, Low dose dexamethasone suppression test (see below). Or, late night salivary cortisol. Or, circadian rhythm i. If normal, Cushings syndrome is unlikely. ii. If anyone is abnormal, perform other tests and repeat the abnormal result. Cushings syndrome is confirmed by using 2 of 3 main tests: i. Failure to suppress serum cortisol with Low doses of oral dexamethasone. ii. Loss of normal circadian rhythm of cortisol, with inappropriately elevated late night serum or salivary cortisol. iii. Increased 24-hour Urine free cortisol. If Cushings syndrome is confirmed, other tests are done to find out the cause (to localize the site of lesion): Serum ACTH If ACTH is Low or undetectable: Adrenal cause is likely. Then ultrasonography, computed tomography or magnetic resonance imaging to find adrenal lesion (tumor or hyperplasia). If no mass is seen, then adrenal vein sampling or adrenal scintigraphy should be done. If ACTH is High: Likely cause in pituitary (Cushings disease) or ectopic ACTH syndrome. Other tests (to see the effect) Electrolytes (hypokalemia). Blood Glucose. Bone mineral densitometry to see osteoporosis. 4 Manual of Clinical Nephrology Scenario Instruction: Examine the abdomen and relevant. Inspection There is an oblique scar mark in the right iliac fossa Left brachiocephalic arteriovenous fistula with development of aneurysm Bruising over the A-V fistula Palpation There is a bean-shaped mass in right iliac fossa, surface is smooth, margin is ill defined, no tenderness, no organomegaly, kidneys are not ballotable, no ascites, bowel sound present and no added sound. Q1. What are the relevants you want to see? To assess graft function Anaemia Edema (other feature of fluid overload) A-V fistula: Whether it is active (prick mark) and functioning (thrill and bruit) Side Effects of Drug (from Head to Toe) Acne, gum hypertrophy, tremor, hirsutism Abdomen: Striae, thinning of skin Fungal infection, viral warts, skin malignancy Blood Hypertension: On Medication/Not Etiology of chronic kidney disease diabetes mellitus prick mark in fingers (Blood glucose testing), insulin injection mark autosomal dominant polycystic kidney disease If removed before transplantation, scar mark may be present Double scar mark Previous native Kidney nephrectomy as per indication Short Cases 5 Any Sign of/Previous Mode of RRT JVC, FVC or peritoneal dialysis catheter scar mark Previous failed allograft: Mass in iliac fossa both right and left Bed side Urine examination Q2. What is your diagnosis? Transplant Kidney Q3. What are the immunosuppressive drugs used in renal transplantation? For induction, biologic agents are used as part of the initial immunosuppressive regimen in Kidney transplant recipient (KTR) For maintenance immunosuppression, CNI (tacrolimus be the first-line CNI), an anti-proliferative agent (mycophenolate mofetil be the first-line agent) and with or without corticosteroid Q4. What are the common side effects of immunosuppressive drugs?",
    "word_count": 519,
    "char_count": 3478,
    "sentence_count": 39,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 2,
      "total_chunks": 33,
      "position": "3/33",
      "content_type": "treatment",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "insulin",
        "dialysis",
        "peritoneal dialysis",
        "fistula",
        "catheter",
        "kidney transplant",
        "edema",
        "hypokalemia",
        "fluid overload"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 3,
    "text": "What are the common side effects of immunosuppressive drugs? CNI: Nephrotoxicity Hypertension and Sodium retention more with cyclosporine Cosmetic: (cid: 2) Cyclosporine gum hypertrophy, hypertrichosis (cid: 2) Tacrolimus Alopecia Metabolic: (cid: 2) Tacrolimus NODAT (cid: 2) Cyclosporine hyperuricemia, dyslipidemia: hypomagnesemia, hyperkalemia: CsA and Tac GI intolerance: Tacrolimus Neurotoxicity: Tremor, headache, insomnia Tacrolimus MMF: GI side effects nausea, Vomiting, diarrhea Bone marrow suppression leukopenia, anemia, thrombocytopenia Azathioprine: Hematologic side effect leukopenia, anemia, thrombocytopenia Pancreatitis rarely, also hepatitis and cholestasis mTOR inhibitors: Nephrotoxicity de novo proteinuria, nephritic syndrome and exacerbation of pre-existing proteinuria (cid: 2) Impaired wound exacerbation healing (cid: 2) Hyperglycemia, hyperlipidemia (cid: 2) Pneumonia (cid: 2) Bone marrow suppression Corticosteroid: Cosmetic changes, growth impairment, osteoporosis, osteonecrosis impaired wound healing, cataract, glucose intolerance and psychologic effects 6 Manual of Clinical Nephrology Q5. How will you monitor drug level? For cyclosporine: C2 level (2-hour post dose)/C0 (12-hour trough) For tacrolimus: C0 level (12-hour trough) For MMF: MPA AUC Q6. Suppose, this patient is a renal allograft recipient for last 2 years, presented to you with several episodes of loose stool for last 3 months which is mucoid and not Blood mixed. He is on tacrolimus, MMF and prednisolone. What are the differentials you will consider? Differential Diagnosis Most common: Immunosuppressive drugs particularly MMF induced CMV colitis Post-transplant lymphoproliferative disease (PTLD) Other differentials: Bacterial infection: C. difficle, C. jejuni, E. coli Viral infection: Norovirus, adenovirus Fungal and parasitic: Microsporidia, cryptosporidia, isospora belli, amoebiasis and giardiasis, Strongyloides stercoralis Also, non-immunosuppressive medication should be considered. Brief Discussion about Fluid Protocol in Post-transplant Period Urine output Type and sequence of IV fluid infusion 100 ml/heart rate Add 50 ml to output DA/NS/DA/NS 100300 ml/heart rate Add 25 ml to output DA/NS/DA/NS/at bedtime 300500 ml/heart rate Give exact amount of output DA/NS/at bedtime 500 ml/heart rate Give 50 ml less to the output DA/at bedtime/NS/at bedtime 5% dextrose in aqua (DA) then 0. 9% normal saline (NS) then 5% dextrose in aqua (DA) then 0. 9% normal saline (NS). at bedtime: Hartmanns solution Warm Ischemia Time and Cold Ischemia Time There are 3 potential periods for ischemic injury during Kidney transplant. First, ischemia during organ retrieval, from the time of cross clamping (or of asystole in non-Heart-beating donors), until cold perfusion is commenced. Second, there is a period of cold ischemia time (CIT), defined as the period wherein the Kidney is transported from donor to recipient on ice or pump perfused under hypothermic conditions. This is followed lastly by a period of warm ischemia time (WIT) during reanastomosis in the recipient (recipient WIT) between the period that the Kidney is taken out of cooling and the time that it is reperfused by the recipients Blood. A prolonged recipient WIT has been associated with poor shortand long-term graft outcomes. Short Cases 7 Delayed Graft Function Delayed graft function (DGF) has been defined as the need for Dialysis within the first week after transplantation. Differential diagnosis of renal allograft dysfunction Ureteric obstruction Renal artery stenosis Glomerulonephritis: Recurrent and de novo Infection: polyomavirus nephropathy recurrent pyelonephritis/vesicoureteric reflux Nephrotoxic agents Late/recurrent acute rejection non-compliance iatrogenic Chronic allograft nephropathy sclerosing non-specific tubulo-interstitial damage chronic cellular rejection chronic humoral rejection calcineurin inhibitor nephrotoxicity transplant glomerulopathy POST-TRANSPLANT Administering antimicrobial therapy to all at-risk patients immediately after transplantation for a defined duration dependent on the perceived duration of risk and net state of immunosuppression.",
    "word_count": 559,
    "char_count": 4167,
    "sentence_count": 18,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 3,
      "total_chunks": 33,
      "position": "4/33",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "nephropathy",
        "proteinuria",
        "sodium",
        "dialysis",
        "kidney transplant",
        "anemia",
        "hyperkalemia"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 4,
    "text": "Post-transplant Antimicrobial Prophylaxis Prophylaxis Regimen Comments Pneumocystis First line: TMP-SMX 6 months TMP-SMX also reduces the incidence jirovecii Second line (sulphur allergies): of Toxoplasma gondii, Listeria monocyAtovaquone, dapsone or aerosolized togenes, and Nocardia asteroids and pentamidine reduces the incidence of UTI in Kidney transplant recipients. Fungal Nystatin S S ( 1 month) or Fluconazole recommended in High-risk fluconazole ( 36 months) recipients (e. g. combined LiverKidney or pancreasKidney transplant recipients, history of coccidioidomycosis, patients who live in endemic areas) CMV Acyclovir, ganciclovir, or valganciclovir Acyclovir for HSP and VZV prophylaxis for patients not on CMV prophylaxis 8 Manual of Clinical Nephrology Main factors contributing to late graft injury and late graft loss Donor factors Deceased donor Kidney (DBO or donation after circulatory death) Female gender Vascular disease Comorbidity Prolonged ischemia time Delayed graft function Recipient risks (nonimmune) Obesity Urinary tract infection Transplant ureteral obstruction Graft pyelonephritis Polyoma (BK) virus nephropathy Calcineurin inhibitor nephrotoxicity Recurrent pyelonephritis Hypertension, dyslipidemia, smoking Diabetes (pre-existing or post-transplantation) Recipients risks (alloimmune) Child or adolescent recipient Variable medication through concentration from malabsorption or nonadherence HLA mismatches, presensitization status (donor-specific HLA alloantibodies) Acute rejection that is severe, corticosteroid resistant, vascular, antibody-mediated or late occurring Late de novo donor-specific antibodies and chronic (antibody-mediated) rejection. Kidney Disease: Improving Global Outcomes GUIDELINE RECOMMENDATIONS INDUCTION THERAPY Starting a combination of immunosuppressive medications before, or at the time of, Kidney transplantation. Including induction therapy with a biologic agent as part of the initial immunosuppressive regimen in Kidney transplant recipients (KTR). An IL2-RA be the first-line induction therapy. Using a lymphocyte-depleting agent, rather than an IL2-RA, for KTRs at High immunologic risk. Initial Maintenance Immunosuppressive Medications Using a combination of immunosuppressive medications as maintenance therapy including a CNI and an anti-proliferative agent, with or without corticosteroids. Tacrolimus be the first-line CNI used. Tacrolimus or CsA be started before or at the time of transplantation, rather than delayed until the onset of graft function. Short Cases 9 Mycophenolate be the first-line anti-proliferative agent. Patients who are at Low immunological risk and who receive induction therapy, corticosteroids could be discontinued during the first week after transplantation. If mTORi are used, they should not be started until graft function is established and surgical wounds are healed. Long-term Maintenance Immunosuppressive Medications Using the lowest planned doses of maintenance immunosuppressive medications by 24 months after transplantation, if there has been no acute rejection. CNIs be continued rather than withdrawn. If prednisone is being used beyond the first week after transplantation, prednisone be continued rather than withdrawn. STRATEGIES TO REDUCE DRUG COSTS If drug costs block access to transplantation, a strategy to minimize drug costs is appropriate, even if use of inferior drugs is necessary to obtain the improved survival and quality of life and other benefits of transplantation compared with Dialysis. Strategies that may reduce drug costs include: Limiting use of a biologic agent for induction to patients who are High-risk for acute rejection Using ketoconazole to minimize CNI dose Using a non-dihydropyridine calcium channel blocker to minimize CNI dose Using azathioprine rather than mycophenolate Using adequately tested bioequivalent generic Using prednisone long-term. MONITORING IMMUNOSUPPRESSIVE MEDICATIONS Measuring CNI in Blood Every other day during the immediate postoperative period until target levels are reached Whenever there is a change in medication or patient status that may affect Blood levels Whenever there is a decline in Kidney function that may indicate nephrotoxicity or rejection. Monitoring CsA using 12-h trough (C0), 2-h post-dose (C2), or abbreviated AUC. Tacrolimus using 12-h trough (C0). MMF levels. mTORi levels.",
    "word_count": 584,
    "char_count": 4384,
    "sentence_count": 22,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 4,
      "total_chunks": 33,
      "position": "5/33",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "kidney function",
        "nephropathy",
        "calcium",
        "dialysis",
        "kidney transplant",
        "quality of life",
        "monitoring",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 5,
    "text": "Tacrolimus using 12-h trough (C0). MMF levels. mTORi levels. TREATMENT OF ACUTE REJECTION (RECOMMENDATIONS) Biopsy should be done before treating acute rejection, unless the biopsy will substantially delay treatment. 10 Manual of Clinical Nephrology Subclinical and borderline acute rejection should be treated. Corticosteroids should be used for the initial treatment of acute cellular rejection. Adding or restoring maintenance prednisone in patients not on steroids who have a rejection episode. Using lymphocyte-depleting antibodies or OKT3 for acute cellular rejections that do not respond to corticosteroids, and for recurrent acute cellular rejection. Treating antibody-mediated acute rejection with one or more of the following alternatives, with or without corticosteroids Plasma exchange; Intravenous immunoglobulin; Anti-CD20 antibody; Lymphocyte-depleting antibody. For patients who have a rejection episode, adding mycophenolate if the patient is not receiving mycophenolate or azathioprine, or switching azathioprine to mycophenolate. TREATMENT OF CHRONIC ALLOGRAFT INJURY (CAI) Kidney allograft biopsy should be done for all patients with declining Kidney function of unclear cause, to detect potentially reversible causes. For patients with CAI and histological evidence of CNI toxicity, reducing, withdrawing, or replacing the CNI is recommended. For patients with CAI, estimated glomerular filtration rate 40 milliliters per minute/1. 73 m2, and Urine total Protein excretion of 500 magnesium per gram Creatinine (or equivalent proteinuria by other measures), replacing the CNI with a mTORi may be done. MONITORING Kidney ALLOGRAFT FUNCTION Measuring Urine volume Every 12 heart rate for at least 24 heart rate after transplantation; Daily until graft function is stable. Measuring Urine Protein excretion, at least Once in the first month to determine a baseline Every 3 months during the first year Annually, thereafter. Measuring serum Creatinine, at least Daily for 7 days or until hospital discharge, whichever occurs sooner 23 times per week for weeks 24 Weekly for months 2 and 3 Every 2 weeks for months 46 Monthly for months 712 Every 23 months, thereafter. Estimating glomerular filtration rate whenever serum Creatinine is measured. Short Cases 11 Including a Kidney allograft ultrasound examination as part of the assessment of Kidney allograft dysfunction. Kidney ALLOGRAFT BIOPSY When there is a persistent, unexplained increase in serum Creatinine. When serum Creatinine has not returned to baseline after treatment of acute rejection. Every 710 days during delayed function. If expected Kidney function is not achieved within the first 12 months after transplantation. When there is new onset of proteinuria; unexplained proteinuria 3. 0 g per gram Creatinine or 3. 0 g/24 heart rate. VIRAL DISEASES BK (Polyoma) Virus Screening all KTRs for BKV with quantitative plasma NAT at least: Monthly for the first 36 months after transplantation Then every 3 months until the end of the first post-transplant year Whenever there is an unexplained rise in serum Creatinine After treatment for acute rejection. Immunosuppressive medications should be reduced when BKV plasma NAT is persistently greater than 10, 000 copies/ml (107 copies/L). Cytomegalovirus CMV prophylaxis: KTRs (except when donor and recipient both have negative CMV serologies) should receive chemoprophylaxis for CMV infection with oral ganciclovir or valganciclovir for at least 3 months after transplantation, and for 6 weeks after treatment with a T-cell-depleting antibody. In patients with CMV disease, weekly monitoring of CMV by NAT or pp65 antigenemia should be done. CMV Treatment All patients with serious (including most patients with tissue invasive) CMV disease be treated with intravenous ganciclovir. CMV disease in adult KTRs that is not serious (e. g. episodes that are associated with mild clinical symptoms) be treated with either intravenous ganciclovir or oral valganciclovir. All CMV diseases in pediatric KTRs be treated with intravenous ganciclovir.",
    "word_count": 593,
    "char_count": 4069,
    "sentence_count": 33,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 5,
      "total_chunks": 33,
      "position": "6/33",
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "medical_entities": [
        "glomerular filtration rate",
        "kidney function",
        "proteinuria",
        "creatinine",
        "magnesium",
        "serum creatinine",
        "screening",
        "monitoring"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 6,
    "text": "All CMV diseases in pediatric KTRs be treated with intravenous ganciclovir. Continuing therapy until CMV is no longer detectable by plasma NAT or pp65 antigenemia. Reducing immunosuppressive medication in life-threatening CMV disease, and CMV disease that persists in the face of treatment, until CMV disease has resolved. Monitoring of graft function closely during CMV disease. 12 Manual of Clinical Nephrology URINARY TRACT INFECTION All KTRs receive UTI prophylaxis with daily trimethoprim-sulfamethoxazole for at least 6 months after transplantation. For allograft pyelonephritis, initial hospitalization and treatment with intravenous antibiotics should be done. PNEUMOCYSTIS Jirovecii pneumonia All KTRs receive PCP prophylaxis with daily trimethoprim sulfamethoxazole for 36 months after transplantation. All KTRs receive PCP prophylaxis with daily trimethoprim-sulfamethoxazole for at least 6 weeks during and after treatment for acute rejection. KTRs with PCP diagnosed by bronchial alveolar lavage and/or lung biopsy be treated with High-dose intravenous trimethoprim-sulfamethoxazole, corticosteroids, and a reduction in immunosuppressive medication. Treatment with corticosteroids for KTRs with moderate to severe PCP. Diabetes MELLITUS Screening for New Onset Diabetes after Transplantation (NODAT) Screening all nondiabetic KTRs with fasting plasma glucose, oral glucose tolerance testing, and/or hemoglobin hemoglobin A1c at least: Weekly for 4 weeks; Every 3 months for 1 year and Annually, thereafter. Screening for NODAT with fasting glucose, oral glucose tolerance testing, and/or hemoglobin hemoglobin A1c after starting, or substantially increasing the dose no, of CNIs, mTORi, or corticosteroids. Managing NODAT or Diabetes Present at Transplantation If NODAT develops, consider modifying the immunosuppressive drug regimen to reverse or ameliorate Diabetes, after weighing the risk of rejection and other potential adverse effects. Consider targeting hemoglobin hemoglobin A1c 7. 07. 5%, and avoid targeting hemoglobin hemoglobin A1c p6. 0%, especially if hypoglycemic reactions are common. In patients with Diabetes, aspirin (65100 magnesium/d) use for the primary prevention of cardiovascular disease be based on patient preferences and values, balancing the risk for ischemic events to that of bleeding. HYPERTENSION Measuring Blood Hypertension at each clinic visit. Maintaining Blood Hypertension at of 130 mm Hg systolic and 80 mm Hg diastolic if 18 years of age. To treat hypertension, use any class of antihypertensive agent; monitor closely for adverse effects and drug interactions; and when Urine Protein excretion 1 g/d for 18 years old, consider an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker as the first-line therapy. Short Cases 13 Scenario CONTINUOUS AMBULATORY PERITONEAL Dialysis (continuous ambulatory peritoneal dialysis) Q1. Examine the abdomen and tell your findings. Ans. Inspection: There is tenckhoff peritoneal catheter Catheter exit site is healthy Abdomen is not distended, flanks are not full, umbilicus inverted Palpation: There is no tenderness There is no organomegaly Percussion: Shifting dullness is not positive Auscultation: Bowel sound is present. Q2. What are the frequency and duration of Dialysis given by this catheter? Ans. Patient performs manual exchange 3 to 5 times in a day. Each exchange taking 30 minutes. Q3. What is the osmotic agent commonly used in continuous ambulatory peritoneal dialysis? Ans. Dextrose (glucose) 1. 5%, 2. 5%, 4. 25% dextrose preparations are commonly used pH 5. 5 Q4. What is the composition of Dialysis solution used in continuous ambulatory peritoneal dialysis? Ans. pH 5. 5 Osmotic agentglucose sodium: 132 mM, calcium: 1. 75 mM, magnesium: 0. 75 mM, Lactate: 35 mM, Bicarbonate: 0 mM 14 Manual of Clinical Nephrology Q5. What are the non-glucose based solutions? Ans. Icodextrin, amino acid-based solution. Q6. Which patients are preferable for continuous ambulatory peritoneal dialysis? Ans. 1. Patient with severe cardiovascular disease 2. Patient with difficult vascular access 3. Patient who desire greater freedom to travel and become active 4.",
    "word_count": 596,
    "char_count": 4183,
    "sentence_count": 54,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 6,
      "total_chunks": 33,
      "position": "7/33",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "sodium",
        "calcium",
        "magnesium",
        "bicarbonate",
        "hemoglobin",
        "antihypertensive",
        "dialysis",
        "peritoneal dialysis",
        "vascular access",
        "catheter"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 7,
    "text": "Patient with difficult vascular access 3. Patient who desire greater freedom to travel and become active 4. Patient who wish to perform home Dialysis 5. Infant and very young children Q7. What are the contraindications of continuous ambulatory peritoneal dialysis? Ans. Unsuitable peritoneum due to the presence of adhesions, fibrosis and malignancy. Q8. What are the advantages of continuous ambulatory peritoneal dialysis? Ans. 1. Less expensive than hemodialysis 2. Can be performed at home 3. Allow patient more independence and freedom to travel 4. Patient can take full responsibility for their treatment 5. Relatively Low cost Q9. What are the disadvantages of continuous ambulatory peritoneal dialysis? Ans. Less efficient than hemodialysis Q10. What are the complications of continuous ambulatory peritoneal dialysis? Ans. 1. Peritonitis: Usually entry of skin contaminants via catheter, bowel organism is less common 2. Catheter exit site infection: Usually skin organism 3. Ultrafiltration failure: Damage of peritoneal membrane, leading to rapid transport of glucose and loss of osmotic gradient 4. Peritoneal membrane failure: Scarring or damage to peritoneal membrane 5. Sclerosing peritonitis Q11. What is the source of peritonitis? Ans. Intraluminal, periluminal, bowel source, hematogenous and transvaginal Q12. What are the common organism of peritonitis? Ans. Gram-positive organism S. aureus, coagulase negative staphylococcal species Gram-negative organism Pseudomonas sp. E. coli Fungi Mycobacterium Polymicrobial growth Culture negative Short Cases 15 Q13. What is the diagnostic criteria of peritonitis? Ans. At least 2 of the following 3 findings should be present: 1. Symptom and sign of peritoneal inflammation Symptoms: Abdominal Pain, nausea and Vomiting, feverish sensation, chills, constipation or diarrhea Signs: Cloudy peritoneal fluid, abdominal tenderness, rebound tenderness, increase temperature, Blood leukocytosis 2. Cloudy peritoneal fluid with an elevated peritoneal fluid cell count (more than 100/mcL) due to predominantly neutrophil (more than 50%) and 3. Demonstration of bacteria in peritoneal effluent by Gram stain or culture Q14. What is the choice of antibiotics in peritonitis? Ans. Empiric antibiotics must cover both gram-positive and gram-negative organisms. Vancomycin or first generation cephalosporin such as cefazolin or cephalothin used in combination with an antibiotic such as ceftazidime or an aminoglycoside. Q15. What is sclerosing peritonitis? Ans. Sclerosing peritonitis is a rare form of peritoneal inflammation which involves parietal and visceral peritoneum characterized by fibrous thickening of peritoneum. Scenario Examination of the lower limbs Inspection Ulcer (site, single, multiple, oozing, gangrene, surrounding skin). Look at the tip of all toes, sole and spaces between the toes. 16 Manual of Clinical Nephrology If gangrene is present, see whether it is dry or wet, demarcation between healthy and unhealthy skin. Color change of skin and hair loss. Amputation of toe (may be). Pigmented scar, small round plaques with raised border in a linear fashion over shin (diabetic dermopathy). Joints (Charcot joint or joint Edema). Thigh wasting, atrophy or hypertrophy (insulin therapy). Palpation: Ask the patient whether the foot is sore. Temperature (warm or cold, compare with other foot). Pulse (arteria dorsalis pedis, posterior tibial), reduced, absent or bounding. Sensation, reduced or absent (see light touch, Pain, joint sense). Vibration and position sense (may be lost due to the posterior column lesion called diabetic pseudotabes). Reflex, reduced or absent, see also plantar response. In some cases, test for proximal myopathy (diabetic amyotrophy, which shows asymmetrical wasting of thigh). Q1. What is your diagnosis? Ans. Foot ulcer Q2. What are the causes of ulcer in diabetes mellitus? Ans. Ischemia. Neuropathy. Combined ischemia and neuropathy. Secondary infection. Trauma. Q3. What is the pathology of ischemic ulcer? Ans. Usually macro vascular, associated with atherosclerosis. Q4. What are the findings, if the ulcer is due to combined neuropathy and ischemia?",
    "word_count": 600,
    "char_count": 4163,
    "sentence_count": 80,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 7,
      "total_chunks": 33,
      "position": "8/33",
      "content_type": "treatment",
      "content_type_confidence": 3,
      "medical_entities": [
        "insulin",
        "dialysis",
        "hemodialysis",
        "peritoneal dialysis",
        "vascular access",
        "catheter",
        "ultrafiltration",
        "edema",
        "neuropathy"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 8,
    "text": "Q4. What are the findings, if the ulcer is due to combined neuropathy and ischemia? Ans. In such case, the findings are: Ulcer is on foot, callosities and Hypertension points. Loss of arch of foot. Sensory loss of all modalities in stocking pattern. Loss of pulsation. Foot is cold, shiny with loss of hair. Short Cases 17 Q5. What are the differences between ischemic and neuropathic ulcers or what are the features of neuropathic and ischemic ulcers? Ans. Causes of neuropathic ulcer: Diabetes mellitus. Leprosy. Polyneuropathy (due to any cause). Tabes dorsalis. Syringomyelia. Amyloidosis. Porphyria. Progressive sensory neuropathy. Features Neuropathic ulcer Ischemic ulcer (arterial) Symptoms No Pain, paraesthesia or tingling may Pain, history of claudication be present Foot High arched, clawing of toes, no trophic Rubor, trophic changes (atrophy change and loss of hair) Area Warm, dry and pink Cold, shiny Pulse Bounding Absent or reduced Sensation Reduced or absent Normal Ulcer Painless and mostly plantar Painful, over heels and toes Reflex Reduced or absent, equivocal plantar Normal response Q6. What is diabetic foot? Ans. Diabetic foot is a group of disorders that occur as complication of Diabetes mellitus. Presence of multiple pathology such as infection, diabetic foot ulcer and neuropathic osteoarthropathy is called diabetic foot syndrome. Q7. What are the features of diabetic foot? How to manage diabetic foot? Ans. 1. Neuropathic: Ulcer (plantar), sepsis, abscess, osteomyelitis, digital gangrene, Charcot joint, High arched and clawing of toes. 2. Ischemic: Ulcer, sepsis, gangrene. Management: Prevention is the main step. Along with Good control of Diabetes, following measures should be taken: 1. Advice to all diabetic patients: Inspect and wash feet every day. Miniaturization of skin, if dry. Cut toe nails regularly, very carefully. Wear suitable Good-fitting shoes. Check footwear for foreign bodies. Change socks or stockings every day. 18 Manual of Clinical Nephrology Avoid walking barefoot. Cover minor cuts with sterile dressings. Do not burst blisters. Avoid over-the-counter corn or callus remedies. Keep feet away from heat (e. g. hot Water, hot sand, fire, radiation). 2. Additional advice to High-risk patients: Do not attempt corn removal. Avoid High and Low temperature. 3. Involve a podiatrist in the care of the patient. 4. Special footwear should be used in Charcot neuroarthropathy. Q8. How to investigate diabetic ulcer? Ans. CBC. Blood Glucose. Urine RME. X-ray of the affected part. Doppler ultrasonography of the lower limb vessels. C/S from pus, if any. If localized area of occlusioneither bypass surgery or angioplasty may be needed. Q9. How to treat a case of diabetic ulcer? Ans. Good control of Diabetes mellitus. Smoking should be stopped. Local dressing and removal of dead tissue. Antibiotic to control secondary infection. Consult with chiropodist. Surgery may be required (removal of callus, amputation or angioplasty). Patients education: Avoid barefoot, tight shoes, careful cutting of nails, avoid weight bearing. Other measures: As in diabetic foot. Liaison should be maintained among physician, chiropodist and surgeon. Short Cases 19 Scenario Instructions Examination of the lower limbs (perform general examination) Presentation of the Case The leg is swollen up to the thigh, red, warm with pitting Edema Tenderness in the calf muscle Superficial veins are prominent and tender. Q1. What is the most possible diagnosis? Ans. Deep vein thrombosis Q2. What are the other possibilities? Ans. Cellulitis Ruptured Baker cyst Post-traumatic calf hematoma Q3. What are the causes of DVT? Ans. Prolonged bed rest or immobilization Pregnancy and puerperium Hypercoagulable state Vascular damage Q4. What are the relevant investigations? Ans.",
    "word_count": 576,
    "char_count": 3807,
    "sentence_count": 87,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 8,
      "total_chunks": 33,
      "position": "9/33",
      "content_type": "evidence",
      "content_type_confidence": 2,
      "medical_entities": [
        "edema",
        "neuropathy"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 9,
    "text": "Ans. Prolonged bed rest or immobilization Pregnancy and puerperium Hypercoagulable state Vascular damage Q4. What are the relevant investigations? Ans. CBC, ESR Serum albumin Doppler ultrasonography of lower limb, D-dimer, venography ANA, anti-ds-DNA, antiphospholipid antibody Antithrombin III, Protein C, Protein S Homocysteine level 20 Manual of Clinical Nephrology Q5. What are the complications of DVT? Ans. Pulmonary embolism Venous gangrene Postphlebitic syndrome Q6. How to treat DVT? Ans. General management Bed rest Use of elastic stockings Relief of Pain by analgesics Intermittent elevation of foot during day Mobilization slowly when the patient is fully anticoagulated Anticoagulation Unfractionated heparin Low molecular weight heparin Oral anticoagulantwarfarin IVC filters if anticoagulation contraindicated Q7. How to prevent DVT? Ans. Early mobilization Leg exercise Elastic stockings Low dose aspirin Low molecular weight heparin Avoid oral contraceptive pill Treat the primary cause Short Cases 21 Scenario Instruction: Examine the arm Inspection: Site of A-V access Remaining part of the arm, shoulder, breast, neck and face Presence of Edema (indicating suspicion of downstream Edema) Presence of collateral veins (indicating suspicion of downstream Edema) Any scar in the chest wallevidence of previous catheterization The presence of face, neck or breast Edema indicating central venous stenosis Presence of aneurysm Edema and redness Palpation: Pulse: (cid: 2) Normally soft pulse (cid: 2) Water hammer pulse/hyperpulsatile pulsein downstream stenosis (cid: 2) Feeble pulse in upstream stenosis Thrill: (cid: 2) Felt as a buzz (cid: 2) It may be continuous/discontinuous (normally present if stenosis or obstruction) Auscultation: (To see the quality of the bruit at the site of anastomosis) (cid: 2) Normallycontinuous (cid: 2) If stenosis presentdiscontinuous bruit 22 Manual of Clinical Nephrology Special test: Pulse augmentation test to evaluate inflow segment (cid: 2) This is performed by complete occlusion of the access several centimeters beyond the arterial anastomosis (cid: 2) Test is considered to be normal if portion of the fistula upstream from the occluding finger demonstrates an augmentation of pulse (cid: 2) Normally: (cid: 3) The thrill should disappear. (cid: 3) The rest of the access upstream to the occluding finger should become hyperpulsatile. If thrill does not disappear, it indicates that there is a side branch of fistula draining (accessory outflow pathway should be suspected). Arm elevation test to assess the outflow tract: (cid: 2) By elevating the extremity and examining the normal collapse of AV fistula (cid: 2) The test is considered abnormal when the fistula remains plump after arm elevation and fails to collapse (cid: 2) This indicates downstream obstruction Possible Locations for Upper Arm AV Fistula A. Conventional 1. Snuffbox (distal-most site) 2. Radiocephalic or Brescia-Cimino (radial artery to forearm cephalic vein at the wrist) 3. Ulnar artery to forearm basilic vein (uncommon) 4. Brachial artery to upper arm cephalic vein (at the elbow) B. Transposed 1. Forearm basilic vein to radial artery at the wrist. 2. Forearm basilic vein to the brachial artery (loop configuration) 3. Forearm cephalic vein to the brachial artery (loop configuration) Complications of AV Fistula/AV Graft Immediate 1. Failure to primary maturation 2. Hemorrhage 3. Infection Delayed 1. Stenosis 2. Thrombosis 3. Inadequate Blood flow 4. Ischemia 5. Edema Short Cases 23 6. Aneurysm 7. Pseudo aneurysm 8. Steal syndrome 9. Infections 10. Extravasation injury 11. SVC or central vein obstruction 12. Burst of fistula Thrombosis of AV Fistula and Graft It is the most common complication of AV access and 8085% of causes of access failure. Causes of Thrombosis 1. Stenosis 2. Vascular endothelial injury 3. Altered Blood coagulability 4. Arterial stenosis 5. Fistula compression 6. Hypovolemia 7. Hypertension 8. Hematoma formation from cannulation injury 9.",
    "word_count": 596,
    "char_count": 4017,
    "sentence_count": 50,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 9,
      "total_chunks": 33,
      "position": "10/33",
      "content_type": "evidence",
      "content_type_confidence": 2,
      "medical_entities": [
        "fistula",
        "edema",
        "exercise"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 10,
    "text": "Altered Blood coagulability 4. Arterial stenosis 5. Fistula compression 6. Hypovolemia 7. Hypertension 8. Hematoma formation from cannulation injury 9. Hypercoagulable state Predisposing Factors 1. High fibrinogen state 2. Reduce level of Protein S and Protein C 3. Factor V Leiden mutation 4. Lupus anticoagulant 5. Increased hematocrit due to treatment with erythropoietin. Prevention 1. Regular monitoring of fistula and graft 2. Avoid hypotension and hypovolemia 3. Avoid early use of graft before maturation 4. Avoid venipuncture and blood pressure measurement in fistula hand. 5. Prophylactic use of aspirin and warfarin (INR 1. 61. 9) Treatment 1. Treatment of AV fistula Surgical and percutaneous intervention 2. Treatment of AV graft: Endoluminal 24 Manual of Clinical Nephrology Pharmacological thrombectomy Percutaneous thrombectomy Surgical thrombectomy Depending upon expertise of the center 3. If there is residual stenosis 85%, then it should be treated with angioplasty. Guidelines for Vascular Access 1. Preferred type: arteriovenous fistula arteriovenous graft Tunneled Non-tunneled 2. Preservation of vein for fistula creation Avoid pricking in this arm Exercise of the hand with a squeezable ball 3. Timing: In chronic kidney disease stage 4 Rule of Sixes Vein diameter should be at least 6 mm Less than 6 mm below the skin Have a Blood flow of at least 600 milliliters per minute Straight segment for cannulation that is at least 6 cm in length Generally, maturation occurs by around 6 weeks after surgery Indication of Access Visualization Flow through a forearm AV fistula commonly averages 500800 milliliters per minute and in graft, flow is sometimes higher, about 1000 milliliters per minute. Flow in upper arm fistulas or graft may be considerably higher. AV fistulas may maintain patency at flows as Low as 200 ml/ min, whereas AV graft begin to clot at access flows between 600 and 800 milliliters per minute. Kidney Disease Outcomes Quality Initiative recommendations are to have the patient referred for access visualization if access flow is 600 milliliters per minute or if the access flow is 1000 milliliters per minute and has decreased by 25% over the preceding months. Size of Artery and Vein for Fistula Creation A forearm fistula was performed only if the diameter of the radial and ulnar arteries was 2. 0 mm at the wrist and no calcification or segmental stenosis was detected. Also with tourniquet in place at the wrist, the cephalic vein diameter had to be at least 2. 5 mm. Short Cases 25 Scenario General Examination of Lower Limbs There are multiple purpura involving both the legs below the knee, some are red and some are dark, some are palpable, some are not and do not blanch on Hypertension. Differential Diagnosis (If the Patient is Child) ITP Henoch-Schnlein purpura (HSP) Q1. What else do you want to see if HSP? Ans. Buttock Q2. What history do you like to take in Henoch-Schnlein purpura (HSP)? Ans. Arthritis, abdominal Pain, bloody diarrhea and urinary complaint (haematuria) Q3. What are the differential diagnoses? Ans. Drug rash ITP SLE Septicemia Thrombotic thrombocytopenic purpura (TTP) 26 Manual of Clinical Nephrology Discussion Small vessel systemic vasculitis predominantly affecting children. Peak incidence age 45 (range generally 211). 2: 1: ratio. Caucasian black patients. More common in winter and early springassociated with an upper respiratory tract infection (with accompanying fever and malaise) in 2/3. IgA plays a critical role in the pathogenesis of HSP (circulating IgA containing immune complexes, IgA deposition in vessel walls and renal mesangium). These abnormalities are associated with IgA1, not IgA2. IgA complexes and complement deposition in target organs and release of inflammatory mediators. Serum IgA elevated in 50%.",
    "word_count": 596,
    "char_count": 3815,
    "sentence_count": 54,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 10,
      "total_chunks": 33,
      "position": "11/33",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "hematocrit",
        "erythropoietin",
        "vascular access",
        "fistula",
        "exercise",
        "monitoring",
        "stage 4"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 11,
    "text": "IgA complexes and complement deposition in target organs and release of inflammatory mediators. Serum IgA elevated in 50%. A small number is ANCA-positive. Clinical Presentation Presents as a tetrad of skin rash, abdominal Pain, arthralgia, and renal involvement. Rash: Skin manifestations usually dominate the clinical picture. Purpuric (usually symmetrical) rash, affecting legs, buttocks (and, less frequently, arms). Abdomen, chest, and face are typically spared. New lesions may develop over several months. Histology: Leucocytoclastic vasculitis with vascular IgA and C3 deposition. Urticaria may also occur. Abdominal: GI manifestations in 3/4 patients. Nausea, Vomiting, diarrhea (may be bloody), colicky Pain (which may be severe), GI bleeding, ileus, infarction, perforation, intussusception, pancreatitis, cholecystitis. Arthralgia: Joint manifestations in 2/3 patients. Usually symmetrical polyarthralgia, mainly involving knees and ankles, wrists and fingers less common. True arthritis and permanent damage extremely rare. Renal involvement: Focal and segmental mesangial proliferative glomerulonephritis presenting as haematuria, proteinuria (which can be nephrotic range), renal impairment and raised blood pressure. A renal biopsy is usually reserved for nephritic/nephrotic presentations, renal impairment, and persistent or heavy proteinuria. The severity of renal sequelae is often not related to the severity of other manifestations. Other: Pulmonary haemorrhage, cerebral vasculitis (headache, irritability, seizures, focal weakness, altered mental state), neuropathies, and orchitis. Prognosis: Usually self-limiting (usually 1 month). Follow-up is recommended Isolated microscopic (and intermittent macroscopic) haematuria may persist, but the prognosis is Good in this situation. Increase blood pressure is also probably more common. The presence of proteinuria is an adverse prognostic sign. Short Cases 27 Nephritic and mixed nephritic/nephrotic presentations have the worse prognosis (1/3 will progress to end-stage renal disease). Estimated as the cause of end-stage renal disease in 1. 53% children overall. In adults, renal involvement is more common. Complete resolution is the norm, but persistent urinary abnormalities (proteinuria) predict a worse prognosis and mandate follow-up. The renal prognosis is worse in adults than in children. Up to 40% will have chronic kidney disease or end-stage renal disease 15 years after biopsy. Recurrence in 1/3 cases, particularly if renal involvement (usually within 6 months). Treatment Usually symptomatic only, e. g. analgesia for arthralgia. Severe skin or GI manifestations may require corticosteroid Treatment of HSP Nephritis in Children (Kidney Disease: Improving Global Outcomes Guideline) Children with HSP nephritis and persistent proteinuria, 0. 51 g/d per 1. 73 m2, are treated with angiotensin-converting enzyme inhibitor or ARBs. Children with persistent proteinuria, 1 g/d per 1. 73 m2, after a trial of angiotensin-converting enzyme inhibitor or ARBs, and glomerular filtration rate 70 milliliters per minute per 1. 73 m2, be treated the same way as for IgA nephropathy with a 6-month course of corticosteroid. Corticosteroid Regimens in Patients with IgA nephropathy References Pozzi C et al. Manno C et al. Regimen Intravenous bolus injections of 6-month regime of oral prednisone 1 g methylprednisolone for 3 days starting with 0. 81 magnesium/kg/d for each at months 1, 3, and 5, followed 2 months and then reduced by by oral steroid 0. 5 magnesium/kg prednisone 0. 2 magnesium/ kg/d per month for the next on alternate days for 6 months 4 months Treatment of crescentic HSP nephritis in children: Children with crescentic HSP with nephrotic syndrome and/or deteriorating Kidney function are treated the same as for crescentic IgA nephropathy. Prevention of HSP nephritis in children: Do not use corticosteroids to prevent HSP nephritis. HSP nephritis in adults: HSP nephritis in adults be treated the same as in children.",
    "word_count": 571,
    "char_count": 4017,
    "sentence_count": 46,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 11,
      "total_chunks": 33,
      "position": "12/33",
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "end-stage renal disease",
        "nephropathy",
        "nephritis",
        "proteinuria",
        "magnesium",
        "ARBs",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 12,
    "text": "HSP nephritis in adults: HSP nephritis in adults be treated the same as in children. 28 Manual of Clinical Nephrology Scenario Instruction Look at the face or examine the face Inspection There are multiple erythematous and scaly rashes on the face along the butterfly distribution, also involving the forehead and cheeks with clear margin. Q1. What are the differential diagnoses? Ans. Systemic lupus erythematosus Discoid lupus erythematosus Dermatomyositis Mixed connective tissue disease Sarcoidosis Drug rash Q2. What else do you want to examine? Ans. Rash in the other parts of the body Mouth ulcer Arthropathy or arthritis Anaemia Proximal myopathy Sensation over skin History of PKDL Drug history Lymphadenopathy or organomegaly Short Cases 29 Q3. What history do you like to take if it is SLE? Ans. Whether the rash is aggravated on exposure to sunlight Drug history Repeated abortion history in female Convulsion, depression, unconsciousness, paralysis or paresis Raynaud phenomenon History of DVT or thromboembolism Family history of SLE Q4. What are the types of SLE according to ARA criteria? Ans. Possible SLE: When 2 criteria are present Probable SLE: When 3 criteria are present Definite SLE: When 4 or more criteria are present Classic SLE: When many criteria are present Q5. What are the drugs causing SLE? Ans. Hydralazine Procainamide Anticonvulsant drugs Phenothiazine Isoniazid Oral contraceptive pill Ace inhibitor Penicillamine Methyldopa Minocycline Q6. What are the presentations of lupus nephritis? Ans. May be asymptomatic Proteinuria Hematuria Presence of cast in Urine acute kidney injury chronic kidney disease Q7. What investigations should be done in SLE? Ans. Urine routine and microscopy examination CBC Blood urea and serum Creatinine CRP Complements ANA 30 Manual of Clinical Nephrology Anti-ds DNA Anti-Smith (Sm) antibody Antiphospholipid antibody 24-heart rate urinary Protein CCR Renal biopsy Skin biopsy Discussion Definitions of response to therapy LN. Complete response: Return of serum creatinine to previous baseline, plus a decline in the urine protein-to-creatinine ratio to 500 magnesium/d (50 magnesium/mmol) Partial response: Stabilization (25%), or improvement of serum creatinine, but not to normal,   plus a 50% decrease in urine protein-to-creatinine ratio. If there was nephrotic range proteinuria (urine protein-to-creatinine ratio 300   magnesium/g 300 magnesium/mmol), improvement requires a 50% reduction in urine protein-to-creatinine ratio, and a urine protein-to-creatinine ratio 300 magnesium/mmol. Deterioration: There is no definition of deterioration in LN to define treatment failure that has been tested prospectively as an indication to change in initial therapy. A sustained 25% increase in serum creatinine is widely used but has not been validated. Regimens for Initial Therapy in Class III/Class IV LN Regimen A. NIH B. Euro-lupus D. Oral cyclophosD. MMF phamide Cyclophosphamide Intravenous Intravenous Oral cyclopho- cyclophocyclopho- sphamide sphamide sphamide 1. 01. 5 magnesium/kg/d 0. 51 g/m2; 500 magnesium; every (maximum dose monthly for 2 weeks for 150 magnesium/d) for 6 months 3 months 24 months MMF MMF up to 3 g/d for 6 months Benefit shown by Yes Yes Yes Yes RCT in proliferative LN Benefit shown by Yes Untested Untested Untested RCT in severe proliferative LN Comments Effective in Effective in Effective in whites, blacks, Effective in whites, whites. Untested Chinese; easy to administer whites, blacks, blacks, in back, Hispanics, and lower cost than Hispanics, Hispanics, Chinese intravenous cyclophoChinese, High Chinese sphamide cost LN, lupus nephritis; MMF, mycophenolate mofetil; RCT, randomized controlled trial. All regimens include corticosteroids: (cid: 129) Oral prednisone, initial dose up to 0. 51 magnesium/kg/d, tapering over 612 months according to clinical response. (cid: 129) Intravenous methylprednisolone is sometimes added initially for severe disease.",
    "word_count": 584,
    "char_count": 3972,
    "sentence_count": 37,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 12,
      "total_chunks": 33,
      "position": "13/33",
      "section": "HSP nephritis in adults:",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "nephritis",
        "proteinuria",
        "creatinine",
        "urea",
        "magnesium",
        "serum creatinine"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 13,
    "text": "(cid: 129) Intravenous methylprednisolone is sometimes added initially for severe disease. Short Cases 31 Criteria for the Diagnosis and Classification of Relapses of LN Mild Kidney relapse Moderate Kidney relapse Severe Kidney relapse Increase in glomerular If baseline Creatinine is: If baseline Creatinine is: haematuria from 2. 0 milligrams per deciliter 177 mol/L, an 2 milligrams per deciliter 177 millimoles per liter, an 5 to 15 red blood cell/hpf, increase of 0. 201. 0 milligrams per deciliter increase of 1. 0 milligrams per deciliter with 2 acanthocytes/hpf 17. 788. 4 mol/L 88. 4 mol/L 2. 0 milligrams per deciliter 177 mol/L, an 2. 0 milligrams per deciliter 177 mol/L, an increase of 0. 401. 5 milligrams per deciliter increase of 1. 5 milligrams per deciliter 35. 4132. 6 millimoles per liter 132. 6 mol/L and/or and/or and/or recurrence of 1 red blood cell If baseline urine protein-to-creatinine ratio is: an absolute increase of cast, white blood cell cast (no 500 magnesium/g 50 magnesium/mmol, an urine protein-to-creatinine ratio 5000 magnesium/g infection), or both increase to 1000 magnesium/g 5000 magnesium/mmol 100 magnesium/mmol 5001000 magnesium/g 50100 magnesium/mmol, an increase to 2000 magnesium/g 200 magnesium/mmol, but less than absolute increase of 5000 magnesium/g 500 magnesium/mmol 1000 magnesium/g 1000 magnesium/mmol, an increase of 2-fold with absolute urine protein-to-creatinine ratio 5000 magnesium/g 500 magnesium/mmol hpf, High-power field; LN, lupus nephritis; red blood cell, red Blood cell; urine protein-to-creatinine ratio, Urine Protein: Creatinine ratio; white blood cell, white Blood cell. Lupus Nephritis Treatment Class I LN (Minimal Mesangial LN) Patients with class I LN be treated as dictated by the extra renal clinical manifestations of lupus. Class II LN (Mesangial Proliferative LN) Treat patients with class II LN and proteinuria 1 g/d as dictated by the extra renal clinical manifestations of lupus. Class II LN with proteinuria 3 g/d be treated with corticosteroids or CNIs as described for MCD Class III LN (Focal LN) and Class IV LN (Diffuse LN)Initial Therapy Initial therapy with corticosteroids, combined with either cyclophosphamide or MMF. If patients have worsening LN (rising serum creatinine, worsening proteinuria) during the first 3 months of treatment, a change be made to an alternative recommended initial therapy, or a repeat Kidney biopsy be performed to guide further treatment. 32 Manual of Clinical Nephrology Class III LN (Focal LN) and class IV LN (diffuse LN)Maintenance Therapy After initial therapy is complete, patients with class III and IV LN receive maintenance therapy with azathioprine (1. 52. 5 magnesium/kg/d) or MMF (12 g/d in divided doses), and Low-dose oral corticosteroids (10 magnesium/d prednisone equivalent). CNIs with Low-dose corticosteroids be used for maintenance therapy in patients who are intolerant of MMF and azathioprine. After complete remission is achieved, maintenance therapy be continued for at least 1 year before consideration is given to tapering the immunosuppression. If complete remission has not been achieved after 12 months of maintenance therapy, consider performing a repeat Kidney biopsy before determining if a change in therapy is indicated. While maintenance therapy is being tapered, if Kidney function deteriorates and/ or proteinuria worsens, treatment should be increased to the previous level of immunosuppression that controlled the LN. Class V LN (Membranous LN) Patients with class V LN, normal Kidney function, and non-nephrotic range proteinuria be treated with antiproteinuric and antihypertensive medications, and only receive corticosteroids and immunosuppressive as dictated by the extra renal manifestations of systemic lupus. Patients with pure class V LN and persistent nephrotic proteinuria be treated with corticosteroids plus an additional immunosuppressive agent: Cyclophosphamide, or CNI, or MMF, or azathioprine.",
    "word_count": 587,
    "char_count": 3992,
    "sentence_count": 30,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 13,
      "total_chunks": 33,
      "position": "14/33",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "kidney function",
        "nephritis",
        "proteinuria",
        "creatinine",
        "magnesium",
        "serum creatinine",
        "antihypertensive",
        "classification"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 14,
    "text": "Class VI LN (Advanced Sclerosis LN) Patients with class VI LN be treated with corticosteroids and immunosuppressive only as dictated by the extra renal manifestations of systemic lupus. General Treatment of LN All patients with LN of any class are treated with hydroxychloroquine (maximum daily dose of 66. 5 magnesium/kg ideal body weight), unless they have a specific contraindication to this drug. Relapse of LN A relapse of LN after complete or partial remission be treated with the initial therapy followed by the maintenance therapy that was effective in inducing the original remission. If resuming the original therapy would put the patient at risk for excessive lifetime cyclophosphamide exposure, then we suggest a noncyclophosphamide-based initial regimen be used. Consider a repeat Kidney biopsy during relapse if there is suspicion that the histologic class of LN has changed, or there is uncertainty whether a rising serum creatinine and/or worsening proteinuria represents disease activity or chronicity. Short Cases 33 Treatment of Resistant Disease In patients with worsening serum creatinine and/or proteinuria after completing one of the initial treatment regimens, consider performing a repeat Kidney biopsy to distinguish active LN from scarring. Treat patients with worsening serum creatinine and/or proteinuria who continue to have active LN on biopsy with one of the alternative initial treatment regimens Nonresponders who have failed more than one of the recommended initial regimens may be considered for treatment with rituximab, intravenous immunoglobulin, or CNIs. Systemic Lupus and Pregnancy Women be counseled to delay pregnancy until a complete remission of LN has been achieved. Cyclophosphamide, MMF, angiotensin-converting enzyme inhibitor, and ARBs not be used during pregnancy Hydroxychloroquine be continued during pregnancy. LN patients who become pregnant while being treated with MMF be switched to azathioprine. If LN patients relapse during pregnancy, they receive treatment with corticosteroids and, depending on the severity of the relapse, azathioprine. If pregnant patients are receiving corticosteroids or azathioprine, these drugs not be tapered during pregnancy or for at least 3 months after delivery. Administration of Low-dose aspirin during pregnancy to decrease the risk of fetal loss. LN in Children Children with LN receive the same therapies as adults with LN, with dosing based on patient size and glomerular filtration rate. 34 Manual of Clinical Nephrology Scenario Look at the picture and give your opinion There are two bullous lesions over the skin of the breast. Lesion over the areola is intact and another one is ruptured. Differential Diagnoses Bullous pemphigoid Pemphigus Lupus erythematosus Drug eruptions Insect bites Toxic epidermal necrolysis Stevens-Johnson syndrome Note: The diagnosis in this case was bullous systemic lupus erythematosus with renal involvement. Scenario Instruction Examine the abdomen/palpate the abdomen Presentation of the Case There are masses in both right and left flanks, left is larger, surface is irregular, margin is rounded or irregular, non-tender, moves with respiration and freely moveable from side to side, not fixed with underlying structure. Get above the Edema is possible. Percussion over the mass is resonant. Short Cases 35 Q1. What may be the differential diagnosis? Ans. Bilateral renal mass which may be due to: Polycystic Kidney disease Bilateral hydronephrosis Diabetic nephropathy in early stage Amyloidosis Rarely bilateral renal cell carcinoma Q2. What is polycystic Kidney disease? Ans. It is an inherited cystic disease of the Kidney. Q3. What are the presentations of adult polycystic Kidney disease? Ans. May be asymptomatic, detected mass on routine examination Discomfort, Pain or heaviness in the loin Recurrent painless hematuria Recurrent urinary tract infection Acute loin Pain or renal colic Features of hypertension Features of renal failure Cerebrovascular accident Q4. What are the other relevant features? Ans.",
    "word_count": 598,
    "char_count": 4052,
    "sentence_count": 34,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 14,
      "total_chunks": 33,
      "position": "15/33",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "glomerular filtration rate",
        "renal failure",
        "nephropathy",
        "proteinuria",
        "creatinine",
        "magnesium",
        "serum creatinine",
        "ARBs",
        "edema"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 15,
    "text": "What are the other relevant features? Ans. Cystic Liver Berry aneurysm Vulvar Heart disease (mitral valve prolapse) Polycythemia Renal stone Q5. What are the causes of acute Pain in this case? Ans. Acute hemorrhage in the cyst Infection in the cyst Renal stone Renal cell carcinoma Q6. What investigations do you suggest? Ans. ultrasonography Urine R/M/E and C/S CBC Renal function test Serum electrolytes High resolution computed tomography/magnetic resonance imaging IVU 36 Manual of Clinical Nephrology Q7. How do you manage the patient? Ans. Plenty of fluid Control of hypertension Control of urinary tract infection Treatment of renal failure Genetic counseling Family screening Aspiration of large cyst (when indicated) 2 Structured Clinical Assessment (SCA) OSPE Station An eighty-year-old patient presented with the complaints of increased frequency of micturition, nocturia, and poor stream of Urine. This is the uroflowmetry tracing. 37 38 Manual of Clinical Nephrology Q1. What is the pattern of uroflowmetry? Ans. a. Obstructive uroflow with severe voiding symptom b. Normal uroflowmetry, Q2. Name some indications of this study. Ans. a. Benign prostatic hypertrophy b. Urinary incontinence c. Neurogenic bladder d. Carcinoma of the prostate e. Urinary blockageobstruction of the urinary tract due to any cause. Q3. What is uroflowmetry? Ans. Uroflowmetry is the measurement of the speed and volume of Urine. This needs an equipment to catch the Urine and measure it while a computer produces the graph. Normally, it is a bell-shaped curve. Normal values Bladder capacity: 400600 ml First sensation: Around 100 ml Detrusor Hypertension (filling): 15 cm of Water Detrusor Hypertension (voiding): 70 cm of Water Peak flow rate: 15 ml/sec Flow time: 1530 sec Q-max: 25 ml/sec Residual volume: 50 ml Structured Clinical Assessment (SCA) 39 OSPE Station 68 years old chronic kidney disease patient presented with fever and cough. This is his chest X-ray. Questions 1. Describe the radiological findings. 2. Mention important findings on chest examination. 3. Name relevant investigations for this patient. 4. How will you manage the patient? Answer Key 1. Dense inhomogeneous opacity involving lower zone of right lung field with air bronchogram: Consolidation. 2. Breath soundbronchial, vocal resonanceincreased, cracklepresent 3. CBC, CRP, sputum Gram stain and culture, Blood culture, serum Creatinine, serum electrolytes, sputum for AFB stain and AFB culture. 4. Antibiotic with dosage adjustment for renal functional status, management of chronic kidney disease. 40 Manual of Clinical Nephrology OSPE Station Questions 1. Describe this picture. 2. What is the diagnosis? 3. What are the probable organisms? 4. What may be the presentation of this patient? 5. How will you investigate this patient? 6. What antibiotic could be used? 7. What are the indications of catheter removal? Answer Key 1. There is a femoral catheter in situ. Exit site shows erythema, crusting, discharge of pus. 2. Exit site infection 3. Staphylococcus Pseudomonas 4. Local Pain Fever associated with chills and rigor Discharge from the exit site Septic shock Structured Clinical Assessment (SCA) 41 5. CBC Blood culture Culture of pus/discharge from the exit site Catheter tip culture (in case of removal of catheter) 6. Combination of cephalosporin and flucloxacillin, linezolid or fimoxyclav may be used. 7. Septic thrombosis Endocarditis Osteomyelitis Severe sepsis with hypotension OSPE Station A 23-year-old lady presented with complaints of recurrent passage of turbid, whitish Urine for last 1 year. She gives history of significant weight loss, amenorrhea, Fatigue and anorexia but no dysuria. This is her Urine sample. Questions a. What are the differential diagnoses? b. What are the important points in history that will help you clinch a diagnosis? c. What are the investigations you need to do? d. Enumerate the management options.",
    "word_count": 600,
    "char_count": 3931,
    "sentence_count": 77,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 15,
      "total_chunks": 33,
      "position": "16/33",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "renal function",
        "renal failure",
        "creatinine",
        "serum creatinine",
        "catheter",
        "fatigue",
        "screening"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 16,
    "text": "c. What are the investigations you need to do? d. Enumerate the management options. 42 Manual of Clinical Nephrology Answer Key a. Chyluria, urinary tract infection b. History of residing in filarial endemic zone, trauma, surgery, pregnancy, malignancy, etc. c. Urine for routine microscopy, triglyceride, sudan 3 test, ether test Urine culture CBC Serum Creatinine Urinary total Protein ultrasonography of whole abdomen and pelvis ICT for filaria computed tomography urogram computed tomography scan of abdomen and pelvis Lymphoscintigram d. Anti-filarial drugs: Diethyl carbamazepine, ivermectin, albendazole Abdominal belt Sclerotherapy: Silver nitrate, povidine iodine, dextrose, hypertonic saline Surgery: Lymphatic disconnection, renal auto transplantation, nephrectomy, lymphovenous anastomosis as per indication. OSPE Station A 60-year-old lady, known case of glomerulonephritis, hypertension, chronic kidney disease presented with back Pain for last 2 years. Here is her X-ray of lumbosacral spine both views: Structured Clinical Assessment (SCA) 43 Questions 1. What are the radiological findings? 2. What are the important points in her history that will help you clinch a diagnosis? 3. How will you manage the patient? Answer Key 1. a. Reduced height of multiple vertebrae (compression collapse) b. Osteopenia c. Fish mouth appearance 2. a. H/O fracture due to tribial trauma b. Drug history (corticosteroid) c. Prolonged immobilization d. Early menopause e. Arthritis 3. Investigations a. Renal function test b. S. calcium, phosphate, magnesium c. S. intact parathyroid hormone, bone alkaline phosphatase d. Bone mineral densitometry e. CBC f. 25-hydroxyvitamin D level, serum FT4, TSH Treatment a. Lifestyle modifications, balanced diet b. Calcium and vitamin D c. Bisphosphonates (alendronate, zoledronic acid, risedronate, ibandronate) d. HRT e. Management of chronic kidney disease (stop offending drug, if any) f. Denosumab 44 Manual of Clinical Nephrology OSPE Station A known case of Diabetes mellitus, hypertension and chronic kidney disease presented with cough and fever for 10 days. This is the chest X-ray PA view: Questions 1. What are the radiological findings? 2. What are the differential diagnoses? 3. What are the important points in history that will help you clinch a diagnosis? 4. Name some important investigations. Answer Key 1. Inhomogeneous opacities with air bronchogram noted in mid and adjacent part of upper zone of left lung field. A thick wall cavitary lesion noted in the lower zone of right lung field. 2. Consolidation, pulmonary tuberculosis, bronchial carcinoma 3. a. Hemoptysis b. Weight loss c. Night sweat d. Smoking history e. History of contact with active TB patient. 4. a. CBC b. Sputum for gram staining. c. Sputum for AFB staining and AFB culture d. Sputum for cytology. e. Sputum for GeneXpert for MTB f. Tuberculin test g. computed tomography scan of chest with computed tomography-guided FNAC h. Bronchoscopy with BAL Structured Clinical Assessment (SCA) 45 OSPE Station A young boy was referred to nephrology department for tingling sensation of upper and lower limb for one month, muscle spasm and cramps of both upper and lower limbs with peri-oral paresthesia. Biochemical analysis shows serum Potassium 2. 5 millimoles per liter, serum magnesium 0. 65 millimoles per liter, hypochloraemia (95 millimoles per liter), serum calcium 1. 8 millimoles per liter, with normal renal function test. Questions a. What is the possible diagnosis? b. What other physical findings that might be present? c. What other investigations may be done? d. Management of the disease. Answer Key a. Gitelman syndrome. b. Latent tetany, arrhythmia. c. ABG analysis which may reveal metabolic alkalosis. Molecular genetic testing may be done. d. High salt diet, oral Potassium and magnesium supplements, spironolactone, indomethacin 46 Manual of Clinical Nephrology OSPE Station 40 years old lady presented with polyarthritis and haematuria.",
    "word_count": 595,
    "char_count": 3982,
    "sentence_count": 49,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 16,
      "total_chunks": 33,
      "position": "17/33",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "renal function",
        "creatinine",
        "potassium",
        "calcium",
        "phosphate",
        "magnesium",
        "parathyroid hormone",
        "vitamin D",
        "serum creatinine"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 17,
    "text": "This is the photograph of her lower limbs. Questions 1. Describe the lower limb lesions. What is the probable diagnosis? 2. Which investigations may be done to establish a diagnosis? 3. What are the complications that may develop? 4. How will you treat? Answer Key 1. Multiple erythematous purpuric rash involving extensor aspect of both lower limbs. Probable diagnosis is Henoch-Schnlein purpura (HSP). 2. Urine R/M/E, serum Creatinine, S. IgA level, CBC, skin biopsy, renal biopsy. 3. Hypertension, renal failure, intussusception, GI bleeding, GI perforation 4. Treatment is mostly symptomatic. In some cases, corticosteroids may be used. Structured Clinical Assessment (SCA) 47 OSPE Station This is a fundal photograph of a 60 years aged patient who presented with blurring of vision. Questions 1. Write down the findings. 2. What may be the cause? 3. What is pathogenesis of hypertensive retinopathy? 4. What measures you have to take to halt progression of retinopathy? Answer Key 1. Cotton wool spot, flame-shaped hemorrhage, blurring of disc margin (left) 2. Hypertension (malignant hypertension) 3. Arteriolar narrowing/ischemia, vascular leakage, retinal Edema. 4. Good Blood Hypertension control 48 Manual of Clinical Nephrology OSPE Station Plain X-ray kidney, ureter, bladder region Questions 1. What are the radiological findings? 2. What are the differential diagnoses? 3. What investigations to be done for diagnosis and management? Answer Key 1. Multiple radio-opaque shadows in both renal areas 2. a. Idiopathic hypercalciuria b. Primary hyperparathyroidism c. Vitamin D intoxication d. Sarcoidosis e. Renal tubular acidosis f. Medullary sponge Kidney g. Tuberculosis 3. a. Urine pH b. Estimation of 24-heart rate urinary, calcium and uric acid c. Serum calcium, Phosphate d. Serum Creatinine and electrolytes e. ultrasonography of kidney, ureter, bladder region f. Serum parathyroid hormone g. computed tomography scan of kidney, ureter, bladder region h. Sestamibi scan of parathyroid glands i. Acid load test j. X-ray chest PA view Structured Clinical Assessment (SCA) 49 OSPE Station Chest X-ray PA view of a chronic kidney disease stage-5 patient. Questions 1. Describe the X-ray. 2. Indication of placing this central venous catheter. 3. Rationale for doing this chest X-ray. 4. What are the types of vascular access for haemodialysis? Answer Key 1. There is a curved radio-opaque shadow having the configuration of a central venous catheter extending from right chest to right atrium (lower part): Possibly tunneled cuffed catheter. 2. As a semi-permanent vascular access for haemodialysis. 3. Purpose of doing the chest X-ray is to see the position of the catheter and to detect any complication like pneumothorax, etc. 4. I. Temporary II. Semi-permanent: a. Tunneled cuffed catheter. III. Permanent: a. A-V fistula and b. A-V graft. 50 Manual of Clinical Nephrology OSPE Station chronic kidney disease 5D patient presented with headache, Vomiting and drowsiness. This is the computed tomography scan of head of the patient: Questions 1. List the computed tomography scan finding. 2. What is the diagnosis? 3. What are the usual presentation of this condition? 4. Indication of surgery in this condition. Structured Clinical Assessment (SCA) 51 Answer Key 1. Hyperdense area with concavity inward involving right frontoparietal area Midline shifted to left 2. Right-sided subdural hematoma 3. Decreased level of consciousness Headache Gait abnormality Cognitive dysfunction Personality change Seizure 4. Thickness greater than 10 mm or a midline shift greater than 5 mm on computed tomography scan If the patient is with GCS score 9 and score decreased by 2 or more from the time of injury to hospital admission. OSPE Station A young man presented with history of generalized Edema of body and diagnosed as a case of nephrotic syndrome.",
    "word_count": 593,
    "char_count": 3862,
    "sentence_count": 78,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 17,
      "total_chunks": 33,
      "position": "18/33",
      "content_type": "evidence",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "renal failure",
        "creatinine",
        "calcium",
        "phosphate",
        "uric acid",
        "parathyroid hormone",
        "vitamin D",
        "serum creatinine",
        "vascular access"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 18,
    "text": "He was treated with full course of oral prednisolone on several occasions with remission and relapse after stopping steroid. Question 1. How will you counsel the patient? Answer Key 1. Greeting and self-introduction 2. This is a disease which affect the filtering system, i. e. glomerulus of Kidney and there is loss of Protein in the Urine which you can detect by strip or by heating the Urine in a spirit lamp. 3. The disease usually respond to steroid but sometimes relapse occur after stopping steroid. Your disease is of that type. 4. We can add second line drug along with steroid and there is every chance of achieving stable remission. 5. But you have to keep in mind that steroid and the other drugs we are planning to give, have got some side effects. Steroid can cause Diabetes mellitus, cataract, muscle weakness, thinning of bone and bone necrosis, hypertension, peptic ulcer disease, acne, skin striation, etc. The other drugs cyclophosphamide may cause bone marrow depression, infertility and Blood may appear in the Urine. 6. Renal biopsy may be needed to pinpoint the diagnosis and planning more specific treatment. 7. During the whole course of treatment you need to be under follow-up for above mentioned side effects and to monitor the response. 8. Do you have any question regarding the disease? 9. Thank you. 52 Manual of Clinical Nephrology OSPE Station A lady of 29 years age, having history of spontaneous abortion in the past, she presented with pancytopenia, proteinuria and hypertension. Questions 1. What is the likely diagnosis? 2. What are the criteria of disease remission in this case? 3. How would you counsel her about future pregnancy? 4. In case of disease flare during pregnancy, what are the treatment options? Answer Key 1. Probable lupus nephritis. 2. Bland urinary sediment, stable renal function, UTP500 magnesium/day, complement normal and anti-ds DNA titer Low. 3. She must be in remission for at least 6 months before conception. 4. Steroid, azathioprine, hydroxychloroquine. IV Ig can be used with caution. OSPE Station A middle-aged man of 40 years presented with history of passing stone with Urine on several occasions. Questions 1. What are the relevant points will you note during history taking including dietary habit? 2. What are the initial investigations to confirm the presence of stone? 3. How will you do metabolic workup in this case? Answer Key 1. History regarding dietary habits specially intake of dairy food, daily fluid intake passage of Blood stained Urine, abdominal Pain, fever with chill and rigor. 2. Urine R/M/E, plain X-ray kidney, ureter, bladder, ultrasonogram of kidney, ureter, bladder, computed tomography urogram, if indicated. 3. Urine pH, estimation of 24 hours urinary calcium, uric acid, S. calcium, phosphate, uric acid and parathyroid hormone. Structured Clinical Assessment (SCA) 53 OSPE Station Middle aged woman presented with recurrent UTI. Questions 1. How do you evaluate the case? 2. What general advice will you give? 3. How to manage the case? Answer Key 1. Some investigations like Urine R/E and C/S, ultrasonogram of kidney, ureter, bladder with measurement of PVR volume, Blood Glucose 2 hours after breakfast can be done to evaluate the case. 2. To double void Urine at bed time, to void Urine after sexual intercourse. To maintain a Good perineal hygiene. 3. Antibiotic according to Urine culture and long-term chemoprophylaxis. OSPE Station Write down important points to be present in the discharge note of a patient who underwent renal transplantation 3 weeks ago. Answer Key 1. Particulars of patient a. Name, age, address b. Primary Kidney disease 2. Case summary a. Salient features b.",
    "word_count": 600,
    "char_count": 3691,
    "sentence_count": 74,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 18,
      "total_chunks": 33,
      "position": "19/33",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "renal function",
        "nephritis",
        "proteinuria",
        "calcium",
        "phosphate",
        "magnesium",
        "uric acid",
        "parathyroid hormone"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 19,
    "text": "Particulars of patient a. Name, age, address b. Primary Kidney disease 2. Case summary a. Salient features b. Important physical findings c. Important investigations 3. Operation note 4. Postoperative course a. Urine output and vitals b. Renal function and electrolyte 5. Treatment and recommendations a. General management b. Immunosuppressive medications 6. Follow-up a. Routine investigation b. Drug level monitoring 54 Manual of Clinical Nephrology OSPE Station What are the steps of permanent catheter insertion through right internal jugular vein for hemodialysis? Answer Key Steps: 1. Take consent after counseling 2. Clean and shave the neck area 3. Draping the area over right side of neck and upper chest 4. Draw 2 points: One at apex of 2 heads of sternocleidomastoid and the other point at upper anterior chest wall. 5. Infiltration of 2% lignocaine around the points mentioned 6. Micro puncture needle is advanced into internal jugular vein 7. Then a guidewire is advanced 8. The micro puncture needle is withdrawn 9. Then a dilator is placed and small incision is made at the puncture site and the dilator is advanced along the guidewire. 10. Remove the dilator 11. Dialysis catheter is advanced through the dilator 12. Guidewire is removed 13. Then the peel away sheath is removed and the catheter is advanced through the subcutaneous tunnel created earlier 14. Then the catheter is flushed with heparin saline 15. Sterile dressing is placed 16. A chest X-ray P/A view is to be done to see the position of the catheter. Structured Clinical Assessment (SCA) 55 OSPE Station Questions 1. Describe the tracing. 2. What is your diagnosis? 3. What are the types of renal involvement? 4. What are the criteria for definitive diagnosis of the disease? Answer Key 1. Monoclonal gammopathy 2. Multiple myeloma 3. Light chain nephropathy, myeloma Kidney, renal stone disease, amyloidosis, prerenal acute kidney injury, hyperuricemia nephropathy, acute interstitial nephritis due to nonsteroidal anti-inflammatory drug. 4. Bone marrow atypical plasma cell more than 10%, lytic bone lesion, monoclonal gammopathy. 56 Manual of Clinical Nephrology OSPE Station A patient has come to you with a laboratory report showing serum Sodium 135, chloride 100, Potassium 2. 0, TCO 32. 2 Questions 1. What is your diagnosis? 2. What other investigations should be done? 3. How do you manage? 4. In spite of adequate replacement of Potassium, serum Potassium is not fully corrected. What additional electrolyte abnormality you will look for? Answer Key 1. Hypokalemic metabolic alkalosis 2. ECG should be done. 3. Intravenous and oral Potassium replacement is to be done. Potassium losing diuretic to be stopped. 4. Serum magnesium should be looked for. OSPE Station A middle-aged man has come to you with laboratory report showing Urine R/E-Protein 2, red blood cell 2030/hpf, red blood cell cast 1. Serum Creatinine 6 magnesium%, serum complement normal, ANA negative, cANCA positive, pANCA negative. Questions 1. What is your diagnosis? 2. How do you manage the patient? Answer Key 1. ANCA associated glomerulonephritis (GPA) with severe renal failure, may be a case of RPGN 2. a. Hemodialysis b. Intravenous methylprednisolone followed by oral prednisolone and cyclophosphamide c. Renal biopsy Structured Clinical Assessment (SCA) 57 OSPE Station Communication Skill A patient of chronic kidney disease stage-4: He is interested to know about renal replacement therapy (RRT). Have a discussion with him about RRT. Answer Key Sl. Steps/Items No. 1. Self-introduction and greetings 2. There are two types of RRT: a. Dialysis b. Transplantation 3. Dialysis is again of two types: a. Hemodialysis b. Peritoneal Dialysis 4. Transplantation is of two types: Living related donor transplantation and cadaver donor transplantation.",
    "word_count": 597,
    "char_count": 3818,
    "sentence_count": 81,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 19,
      "total_chunks": 33,
      "position": "20/33",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "renal function",
        "renal failure",
        "nephropathy",
        "nephritis",
        "creatinine",
        "sodium",
        "potassium",
        "magnesium"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 20,
    "text": "Transplantation is of two types: Living related donor transplantation and cadaver donor transplantation. In living related donor, first and second degree relatives like parents, siblings, uncle and aunts, grandparents, nephews, nieces and spouses are included. In cadaver donor transplantation brain dead persons in the ICU are the source of Kidney. 5. In living donor transplantation, the age of the donor should be between 18 and 65 years. In cadaver donation, age of donor is between 2 and 70 years. 6. For hemodialysis A-V fistula is to be constructed and for peritoneal Dialysis special type of catheter is to be placed in the abdomen. 7. A patient could be switched from one option of RRT to another. 8. Survival is better in transplantation than hemodialysis. 9. Do you want to know any other aspects of RRT? 10. Thanks giving. 58 Manual of Clinical Nephrology OSPE Station Look at the ultrasonographic image. 1. What is the renal anomaly shown in this image? 2. How this patient may present to you? Answer Key 1. Demonstration of alteration of renal outlines, an isthmus or band of renal tissue across the midline of abdomen connecting the lower poles of the kidneys and the kidneys appeared inverted pyriform shape (horseshoe Kidney). 2. Abdominal Pain Abdominal mass Urinary tract infection May be asymptomatic OSPE Station A young female patient of 34 years presented to you with microscopic hematuria, proteinuria (2 g/day), normotensive and normal renal function. a. What are the differential diagnoses? b. Plan your investigations in this case. c. How do you manage this case? Answer Key a. Mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, IgA nephritis, lupus nephritis, vasculitis. b. Serum C4, C3, ANA, AntidsDNA, cANCA, pANCA, ultrasonography of kidney, ureter, bladder, renal biopsy. c. angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, for 36 months and specific treatment according to diagnosis when indicated. Structured Clinical Assessment (SCA) 59 OSPE Station 1. Enumerate the steps in continuous ambulatory peritoneal dialysis catheter insertion. Answer Key 1. Patient preparation: Procedure to be explained Supine position of the patient Shaving of abdominal wall Exit site identification Sterilization and draping of the area Infiltration of local anesthesia 2. Catheter insertion: An incision through the anterior rectus sheath The posterior rectus sheath has been exposed, a purse-string suture has been made, and a 5 mm incision reaching the peritoneal cavity is being created with a scalpel A purse-string suture of peritoneum and rectus fascia is tied securely between the bead and the flange The flange is anchored with four 20 monofilament, non-absorbable sutures into the posterior rectus sheath at the 6, 9, 12, and 3 oclock positions The catheter is passed through the incision centered above the transverse incision A subcutaneous pocket is made to the level of skin marking to accommodate the bent portion of the catheter and the external cuff A trochar is attached and passed through the pocket and the external exit site. The piercing trochar is the same diameter as the tubing Finally, the surgical/incision site is closed in layers 60 Manual of Clinical Nephrology OSPE Station Given the chest X-ray P/A view and serological report of a patient. a. What is your diagnosis? b. What are the investigations to be done for establishing renal involvement? c. How will you manage such a case with deteriorating renal function? Answer Key a. GPA b. Urinalysis, renal function test and renal biopsy c. IV Methylprednisolone followed by oral prednisolone and cyclophosphamide OSPE Station Data Interpretation Serum Sodium 125 milliequivalents per liter Urine osmolality 285 millimoles per liter a. What is the possible diagnosis? b. What other investigations to be done?",
    "word_count": 597,
    "char_count": 3862,
    "sentence_count": 48,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 20,
      "total_chunks": 33,
      "position": "21/33",
      "section": "Transplantation is of two types:",
      "content_type": "dietary",
      "content_type_confidence": 2,
      "medical_entities": [
        "renal function",
        "nephritis",
        "proteinuria",
        "sodium",
        "dialysis",
        "hemodialysis",
        "peritoneal dialysis",
        "fistula",
        "catheter"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 21,
    "text": "What is the possible diagnosis? b. What other investigations to be done? c. How to manage? Structured Clinical Assessment (SCA) 61 Answer Key a. SIADH b. Plasma osmolality, serum Creatinine, serum uric acid, 24 hours urinary Sodium excretion c. Oral fluid intake 1 L/day, oral Sodium chloride. OSPE Station Write down the discharge note of a patient of membranous nephropathy who is put on ponticelli regimen. Answer Key IV methylprednisolone 1 gm/dayday 13 followed by oral prednisolone 0. 5 magnesium/ kg/day for 27 days followed by oral cyclophosphamide 2 magnesium/kg/day for 30 days. Total three such cycles in 6 months. CBC should be done at 2 weeks interval during the treatment with cyclophos phamide if TC of white blood cell 4000/mm3, reduce the dose of cyclophosphamide and if TC of white blood cell 3000/mm3, then stop cyclophosphamide. OSPE Station A 35 years old women presented with 1-week history of muscle weakness and shortness of breath. Her present medical history is unremarkable except arthralgia and dry eye. Her lab reports show: ESR 125 mm in 1st hour, S. sodium 137 millimoles per liter, S. potassium 1. 6 millimoles per liter, S. chloride 115 millimoles per liter, HCO 9 millimoles per liter, blood urea nitrogen 16 milligrams per deciliter, S. Creatinine 0. 8 milligrams per deciliter, arterial 3 pH 7. 2, PaCO 26 mm Hg, PaO 115 mmHg. 2 2 Questions 1. What is the acidbase disorder? 2. What may be the underlying cause? 3. Which disease is responsible for this scenario? 4. What other investigations you want to do? Answer Key 1. Metabolic acidosis with respiratory compensation 2. Type I renal tubular acidosis 3. Primary Sjgrens syndrome 4. Acid load test, serum calcium and phosphate, RA test, ANA, anti-SSA (Ro), antiSSB (La), urinary pH, lip biopsy/labial salivary gland biopsy 62 Manual of Clinical Nephrology OSPE Station A young man of 28 years of age presented with increased frequency of micturition. He underwent thorough investigations which were normal. How will you manage and counsel him? Answer Key 1. Greetings 2. Self-introduction 3. Explanation of the condition: It may be an emotional not physical condition It could be due to increase Water intake He may be unable to recognize full bladder Stress may be another causative factor 4. Assurance There is no health risk Only psychological impacts like frustration, guilty feeling, embarrassment and Low self-esteem 5. Management Lifestyle modification Restrict Water intake, avoid caffeine Micturition training Behavioral therapy Conditioning device Positive reassurance Medication 6. Drug therapy DDAVP Oxybutynin 7. Do you have any question? 8. Thank you. Structured Clinical Assessment (SCA) 63 OSPE Station A 52 years old patient on maintenance hemodialysis presented with Low grade evening rise of temperature, night sweating and weight loss for last 3 months. On clinical examination, he is moderately anemic and there is right-sided cervical lymph adenopathy. a. Plan two important investigations to reach diagnosis. b. Discuss management of extra pulmonary tuberculosis in a patient on maintenance hemodialysis. Answer Key a. Tuberculin test lymph node biopsy b. i. Rifampicin and isoniazid for 9 months in usual daily doses. ii. Pyrazinamide should be administered in a doses of 25 to 30 magnesium/kg body weight; 3 times/week. iii. Ethambutol can be given at a dose of 15 to 25 magnesium/kg body weight; 3 times/ week for patients on regular hemodialysis. iv. Pyridoxin to be given in a dose of 20 magnesium twice daily. v. Drugs may be given after hemodialysis to avoid premature drug removal. OSPE Station A young man of 35 years age presented with scanty micturition and Edema of body.",
    "word_count": 593,
    "char_count": 3695,
    "sentence_count": 57,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 21,
      "total_chunks": 33,
      "position": "22/33",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "nephropathy",
        "creatinine",
        "urea",
        "sodium",
        "potassium",
        "calcium",
        "phosphate",
        "magnesium",
        "chloride",
        "uric acid"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 22,
    "text": "OSPE Station A young man of 35 years age presented with scanty micturition and Edema of body. He gives history of participating in a marathon race one day ago. a. What is the likely diagnosis? b. Name some important early complications. c. What investigations will you do? d. Mention mechanism of acute kidney injury in this case. Answer Key a. acute kidney injury due to rhabdomyolysis b. Early complications Hyperkalemia Hypocalcaemia Cardiac arrhythmia c. Serum Creatinine, electrolytes, Creatinine kinase, calcium, phosphate, uric acid, Urine R/M/E, Urine for myoglobin d. Mechanism of acute kidney injury Tubular obstruction by cast formation Pre-renal due to hypovolemia Direct myoglobin toxicity Free radical injury produced by heam 64 Manual of Clinical Nephrology OSPE Station Two weeks after renal transplantation a patient developed fever, unilateral leg Edema and deterioration of renal function. a. What are the differential diagnoses? b. What are the important investigations to confirm diagnosis? c. How do you manage a lymphocele in a post-transplant patient? Answer Key a. DVT, lymphocele, urinoma, acute rejection. b. ultrasonography of transplant Kidney, duplex study of the transplant Kidney and lower limb vessels transplant Kidney biopsy (if indicated) c. i. Use of sclerosing agent ii. Peritoneal shunt when indicated OSPE Station A Blood report of a young chronic kidney disease patient reveals calcium 7 magnesium%, inorganic phosphate 8 magnesium %, intact parathyroid hormone 800 pg/ml, serum Creatinine 6 magnesium%. a. What could be the symptoms? b. What is your diagnosis? c. What will be your management plan? Answer Key a. Pruritus, bone Pain. b. chronic kidney disease with secondary hyperparathyroidism c. Dietary phosphate restriction, proper hydration, use of phosphate binder and oral calcitriol 3 Instrument and Specimen Instrument Questions 1. Identify the instrument. 2. Describe different parts of the instrument. 3. Use of this instrument. 4. Indication and contraindication of renal biopsy. Answer Key 1. Bioptygun 2. Handle, spring, button, trocar, cannula with guard. 3. Used for solid organ biopsy, e. g. Kidney, Liver, prostate, breast, etc. 4. Indications of renal biopsy: Glomerulonephritis, isolated hematuria of glomerular origin, significant proteinuria, systemic disease affecting Kidney. Unexplained renal failure with normal sized Kidney, transplant Kidney (graft dysfunction/protocol). Contraindications: Bleeding diathesis, uncontrolled hypertension, non-cooperation 65 66 Manual of Clinical Nephrology Instrument Questions 1. Identify the specimen. 2. What are the different parts? 3. What are the different types? 4. What are the uses? 5. How is it sterilized? Answer Key 1. This is a Low flux, moderate efficiency, hollow fiber dialyzer. 2. Basically, the dialyzer shell is a box or tube having: Header Tube sheet Blood inlet and outlet Hollow fibre Jacket Solution inlet and outlet 3. Types of dialyzer: Hollow fibers dialyzer Parallel plates dialyzer Instrument and Specimen 67 Types of membranes: a. Regenerated cellulose b. Modified cellulose c. Synthetic 4. For hemodialysis in acute kidney injury and chronic kidney disease and sometimes to remove some toxins and sometimes to treat fluid overload. 5. Mode of sterilization: Electron beam  -irradiation Steam autoclaving or Ethylene oxide gas. Instrument Questions 1. Identify the instrument. 2. What are the different parts? 3. What are the indications of central venous catheterisation? 4. What are the contraindications of central venous catheterisation? 5. What are the complications of central venous catheterisation? 6. What are the types of vascular access? 68 Manual of Clinical Nephrology Answer Key 1. Femoral non-cuffed venous catheter: 20 cm (length) 2. Parts A. Intravascular part: Terminal hole Side hole B. Extravascular part: Lumen Clamp Connector part with cap 3. a. Urgent hemodialysis b. Plasmapheresis c. Hemodiafiltration and d. Total parenteral nutrition 4. a. Bleeding disorder b.",
    "word_count": 595,
    "char_count": 4020,
    "sentence_count": 77,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 22,
      "total_chunks": 33,
      "position": "23/33",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "renal function",
        "renal failure",
        "proteinuria",
        "creatinine",
        "calcium",
        "phosphate",
        "magnesium",
        "uric acid"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 23,
    "text": "Urgent hemodialysis b. Plasmapheresis c. Hemodiafiltration and d. Total parenteral nutrition 4. a. Bleeding disorder b. Large hematoma c. Local infection 5. Complications of central venous catheterisation a. Immediate complications (depending on the site of catheterisation) Arterial puncture (all) Pneumothorax (IJ, SC) Hemothorax (IJ, SC) Arrhythmias (IJ, SC) Air embolism (all IJ, SC F) Perforation of cardiac chamber (IJ, SC) Pericardial tamponade (IJ, SC) Retroperitoneal hemorrhage (F) b. Delayed complications Thrombosis (all) Infection (all) Central venous stenosis (SC IJ) Arteriovenous fistula (all) Fibrin sheet formation Dysfunction Dislocation and malposition Device damage Lack of Blood return Biofilm formation Instrument and Specimen 69 c. Injury to adjacent structures Brachial plexus (IJ, SC) Recurrent laryngeal nerve (IJ, SC) 6. Types of vascular access: a. Temporary Dialysis catheter (uncuffed catheter) Femoral Jugular Subclavian b. Semi-permanent (tunnel and cuffed catheter) Permcath Dialysis catheter c. Permanent: AV fistula PTFE graft Specimen Q1. Identify the specimen. Ans. continuous ambulatory peritoneal dialysis fluid with drain bag. Q2. What is the composition of Dialysis solution used in continuous ambulatory peritoneal dialysis? Ans. pH 5. 5 Osmotic agent: Glucose sodium: 132 mM, calcium: 1. 75 mM, magnesium: 0. 75 mM, lactate: 35 mM, bicarbonate: 0 mM Q3. What are the buffers used in continuous ambulatory peritoneal dialysis fluid with its disadvantages? Ans. Lactate based: Bioincompatible, normal function of peritoneal cells is impaired Bicarbonate based: Precipitation of calcium, magnesium, caramelization of glucose at physiological pH during sterilization. 70 Manual of Clinical Nephrology Q4. Which patients are preferable for continuous ambulatory peritoneal dialysis? Ans. 1. Patient with severe cardiovascular disease 2. Patient with difficult vascular access 3. Patient who desires greater freedom to travel and becomes active 4. Patient who wish to perform home Dialysis 5. Infant and very young children Q5. What are the contraindications of continuous ambulatory peritoneal dialysis? Ans. Absolute Unsuitable peritoneum due to presence of adhesions, fibrosis and malignancy. Patient or caregiver unable to be trained adequately for the technique Inguinal, umbilical or diaphragmatic hernia Ileostomy or colostomy Abdominal wall infections or intra-abdominal sepsis, e. g. active diverticular disease Relative Morbid obesity (inadequate clearance) Huge polycystic kidneys (insufficient intraperitoneal space) Severe gastroparesis (worsening Vomiting) Severe lung disease (diaphragmatic splinting) Q6. What are the advantages of continuous ambulatory peritoneal dialysis? Ans. 1. Less expensive than hemodialysis 2. Can be performed at home 3. Allow patient more independence and freedom to travel 4. Patient can take full responsibility for their treatment 5. Relatively Low cost Q7. What are the complications of continuous ambulatory peritoneal dialysis? Ans. 1. During catheter insertion Preperitoneal placement Blood tinged Dialysis effluent Serious complications a. Large Blood vessel injury b. Bladder injury c. Bowel injury 2. Infections a. Catheter exit site infection b. Tunnel infection c. Peritonitis 3. Noninfectious a. Catheter related Instrument and Specimen 71 i. Catheter obstruction ii. Malposition iii. Pericatheter leak iv. Cuff extrusion v. Pain during inflow or outflow b. Membrane related i. Ultrafiltration failure ii. Sclerosing encapsulating peritonitis c. Hydrothorax d. Hemoperitoneum e. Hypoalbuminaemia f. Hyperglycaemia g. Hypertriglyceridemia Q8. What are the causes of cloudy effluent? Ans. 1. Culture positive infectious peritonitis 2. Infectious peritonitis with sterile culture 3. Chemical peritonitis 4. Calcium channel blockers 5. Eosinophilia of the effluent 6. Hemoperitoneum 7. Malignancy 8. Chylous effluent 9. Specimen taken from dry abdomen Q9. What are the indications for continuous ambulatory peritoneal dialysis catheter removal? Ans. 1. Refractory peritonitis 2. Relapsing peritonitis 3. Refractory exit site and tunnel infection 4. Fungal peritonitis 5. Catheter removal may also be considered for: a. Repeated peritonitis b. Mycobacterial peritonitis c. Multiple enteric organism Q10.",
    "word_count": 590,
    "char_count": 4292,
    "sentence_count": 75,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 23,
      "total_chunks": 33,
      "position": "24/33",
      "content_type": "dietary",
      "content_type_confidence": 3,
      "medical_entities": [
        "sodium",
        "calcium",
        "magnesium",
        "bicarbonate",
        "nutrition",
        "dialysis",
        "hemodialysis",
        "peritoneal dialysis",
        "vascular access",
        "fistula"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 24,
    "text": "Catheter removal may also be considered for: a. Repeated peritonitis b. Mycobacterial peritonitis c. Multiple enteric organism Q10. How to prepare patients for continuous ambulatory peritoneal dialysis catheter insertion? Ans. Best practices in patient preparation for peritoneal catheter implantation Preoperative assessment to select the most appropriate catheter type, insertion site, and exit site location Bowel preparation the day before the procedure: 2 L of polyethylene glycol solution, enema, or stimulant suppository Shower on the day of the procedure with chlorhexidine soap wash of the planned surgical site 72 Manual of Clinical Nephrology Removal of body hair in the preoperative holding area, preferably with electric clippers Empty the bladder before procedure, otherwise a Foley catheter should be inserted Single preoperative dose of prophylactic antibiotic to provide antistaphylococcal coverage Q11. Describe procedure for continuous ambulatory peritoneal dialysis catheter insertion. Ans. Best practices for peritoneal dialysis catheter insertion Operative personnel are attired in cap, mask and sterile gown and gloves Surgical site is prepped with chlorhexidinegluconate scrub, povidoneiodine (gel or scrub), or other suitable antiseptic agent and sterile drapes applied around the surgical field Peritoneal catheter is rinsed and flushed with saline and air squeezed out of the Dacron cuffs by rolling the submerged cuffs between fingers. Paramedian insertion of the catheter through the body of the rectus muscle Deep catheter cuff positioned within or below the rectus muscle Pelvic location of the catheter tip Catheter flow test performed to confirm acceptable function Skin exit site directed lateral or downward (not upward) Subcutaneous tunneling instrument should not exceed the diameter of the catheter Exit site should be smallest skin hole possible that allows passage of the catheter Position subcutaneous cuff 24 from the exit site No catheter anchoring sutures at the exit site Attach transfer (extension) set at time of procedure Exit site protected and catheter immobilized by nonocclusive dressing Q12. Name some commonly available Dialysis solution. Ans. Commonly available peritoneal Dialysis solution formulations ManupH Osmotic sodium calcium magnesium Lactate BicarPouches facturer agent (mM) (mM) (mM) (mM) bonate (mM) Dianeal Baxter 5. 5 Glucose 132 1. 75 0. 75 35 0 1 PD1 Dianeal Baxter 5. 5 Glucose 132 1. 25 0. 25 40 0 1 PD4 Stay safe FMC 5. 5 Glucose 134 1. 75 0. 5 35 0 1 2/4/3 Stay safe FMC 5. 5 Glucose 134 1. 25 0. 5 35 0 1 17/9/18 Contd. Instrument and Specimen 73 Contd. ManupH Osmotic sodium calcium magnesium Lactate BicarPouches facturer agent (mM) (mM) (mM) (mM) bonate (mM) Nutrineal Baxter 6. 5 Amino 132 1. 25 0. 25 40 0 1 acids Extraneal Baxter 5. 5 lcodextrin 132 1. 75 0. 25 40 0 1 Physioneal Baxter 7. 4 Glucose 132 1. 75 0. 25 10 25 2 35 Physioneal Baxter 7. 4 Glucose 132 1. 25 0. 25 15 25 2 40 Balance FMC 7. 4 Glucose 134 1. 25 0. 5 35 25 2 1. 75 Bicavera FMC 7. 4 Glucose 134 1. 75 0. 5 0 34 2 These may differ slightly in name and in formulation from region to region. All glucose-based solutions are available in three strengths (1. 36, 2. 27, and 3. 86 magnesium/ dL of glucose, equivalent to 1. 5, 2. 5, and 4. 25 milligrams per deciliter of dextrose as glucose monohydrate). To convert calcium from millimoles per liter (mM) to milligrams per deciliter multiply by 4. To convert magnesium from millimoles per liter (mM) to milligrams per deciliter multiply by 2. 43. Fresenius Medical Care (FMC) Instrument Q1. Identify the instrument. Ans. continuous ambulatory peritoneal dialysis catheter Q2.",
    "word_count": 594,
    "char_count": 3675,
    "sentence_count": 59,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 24,
      "total_chunks": 33,
      "position": "25/33",
      "section": "Catheter removal may also be considered for:",
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "medical_entities": [
        "sodium",
        "calcium",
        "magnesium",
        "dialysis",
        "peritoneal dialysis",
        "catheter"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 25,
    "text": "43. Fresenius Medical Care (FMC) Instrument Q1. Identify the instrument. Ans. continuous ambulatory peritoneal dialysis catheter Q2. What are the techniques of peritoneal dialysis catheter implantation? Ans. Percutaneous, surgical, laparoscopic Q3. What are the materials used in continuous ambulatory peritoneal dialysis catheter? Ans. Silicon, polyurethane 74 Manual of Clinical Nephrology Q4. What are the steps of handwash? Ans. Instrument Q1. Identify the instrument. Ans. Blood lines for hemodialysis. Q2. What are the parts? Ans. Arterial line, venous line, air trap, clamps. Instrument and Specimen 75 Q3. What are the functions of air trap chamber? Ans. 1. Reduce foaming 2. Air removal Q4. What is the priming volume of Blood line? Ans. 100150 ml Q5. What is extracorporeal circuit? Ans. Blood line with dialyzer is called extracorporeal circuit. Q6. What is the priming volume of extracorporeal circuit? Ans. 160270 ml Q7. What are the factors favoring clotting of the extracorporeal circuit? Ans. Low Blood flow High hematocrit High ultrafiltration rate Dialysis access recirculation Intradialytic Blood and Blood product transfusion Intradialytic lipid infusion Use of drip chambers (air exposure, foam formation, turbulence) Q8. Mention signs of clotting of extracorporeal circuit. Ans. Extremely dark Blood Shadows or black streaks in the dialyzer Foaming with subsequent clot formation in drip chambers and venous trap Rapid filling of transducer monitors with Blood Teetering (Blood in the post-dialyzer venous line segment that is unable to continue into the venous chamber but falls back into the line segment) Presence of clots at the inflow dialyzer header 76 Manual of Clinical Nephrology Specimen Q1. Identify the specimen. Ans. Hemodialysis fluid Q2. What are the composition? Ans. Compartment A: Acid concentrate contains a small amount of acetic or citric acid plus Sodium, Potassium, calcium, magnesium, chloride, and dextrose (optional). The Low pH of the acid concentrate keeps the calcium and magnesium in solution, even in concentrated form. Compartment B: Bicarbonate concentrate Q3. What are the disadvantages of bicarbonate-based Dialysis solution? Ans. 1. Bacterial contamination (bicarbonate is excellent medium for bacterial growth) 2. Post-Dialysis acute metabolic alkalosis 3. Must be used within 24 hours after mixing 4. Liquid B is not stable Instrument and Specimen 77 Composition of a standard hemodialysis solution Component Concentration (mM) Sodium 135145 Potassium 23 Calcium 1. 251. 75 (2. 532. 5 milliequivalents per liter) Magnesium 0. 250. 375 (0. 50. 75 milliequivalents per liter) Chloride 98124 Acetatea 38 Citratea 0. 81. 0 (2. 43. 0 milliequivalents per liter) Bicarbonate 2535 Glucose 011 pCO 40110 (mm Hg) 2 pH 7. 17. 3 (units) aTable acetate or citrate is added in the form of acetic acid, Sodium diacetate, or citric acid to the acid concentrate. When mixed with the bicarbonate concentrate, the hydrogen ion from either of these acids reacts with bicarbonate to form CO (i. e. carbonic acid) to establish 2 a buffer system. Instrument Questions a. Identify the specimen. b. What are the different parts of the instrument? c. Mention the use of this instrument in nephrology practice. d. Describe the procedure done by the instrument.",
    "word_count": 501,
    "char_count": 3294,
    "sentence_count": 79,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 25,
      "total_chunks": 33,
      "position": "26/33",
      "section": "43. Fresenius Medical Care",
      "content_type": "dietary",
      "content_type_confidence": 3,
      "medical_entities": [
        "sodium",
        "potassium",
        "calcium",
        "magnesium",
        "chloride",
        "bicarbonate",
        "hematocrit",
        "dialysis",
        "hemodialysis",
        "peritoneal dialysis"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 26,
    "text": "c. Mention the use of this instrument in nephrology practice. d. Describe the procedure done by the instrument. 78 Manual of Clinical Nephrology Answer Key a. Permcath b. Lumen cap, lumen lock, biluminal channel, Dacron cuff, catheter lumen and catheter tip c. Permcath insertion for hemodialysis d. Greetings Self-introduction Explain the procedure Explain purpose of the procedure Take written consent for the procedure Positioning on the back Determine the most appropriate site for vascular catheter insertion The overlying skin where the catheter is to be inserted is cleaned and covered with a sterile surgical drape Wear sterile gowns and gloves Numb the area with a local anesthetic A very small skin incision is made at the site The vein is punctured with a needle (usually the jugular vein at the base of the neck). A small guidewire is advanced into the large central vein A second small skin incision may be made below the first A tunnel under the skin is then created. Using X-ray guidance, the catheter is placed through the tunnel into the vein and a tunnel under the skin is then created The catheter is placed through the tunnel into the vein, and the tip of the catheter is placed into the large vein Stitches at the end of the tunnel to help keep the catheter firmly in place An X-ray may be performed after the procedure Close the procedure with proper gauze and bandage Ask for any discomfort End up with thanks 4 Radiology and Imaging Images Q1. Describe the images Ans. This is the IVU (intravenous urogram), control and 1 hour film, showing irregular radio-dense shadow of variable size and shape involving both kidneys. There is also radio-dense shadow in the region of urinary bladder. Pelvicalyceal system is well visualized. 79 80 Manual of Clinical Nephrology Q2. What is the diagnosis? Ans. Bilateral renal calculi with bladder stone. Q3. What are the dye used? Ans. Ionic (uro video) Non-ionic (Iopamiro) Q4. Mention the time required for visualization of urinary tract in the above film. Ans. 1. Nephrogram (within 1 minute) 2. Calyceal system (510 minutes) 3. Ureter (5 minutes) 4. Bladder (15 minutes) Q5. How does the patient present? Ans. 1. Asymptomatic 2. Loin Pain 3. Hematuria 4. Dysuria 5. Fever Image Q1. Describe the image. Ans. This is X-ray kidney, ureter, bladder region showing multiple radio-dense shadow of variable size and shape, coalesce with each other in the both kidneys, gives shape of the Kidney. Radiology and Imaging 81 Q2. What is the diagnosis? Ans. Nephrocalcinosis Q3. What are the probable causes? Ans. 1. Hyperparathyroidism 2. Distal renal tubular acidosis 3. Sarcoidosis 4. Vitamin D intoxication 5. Primary oxalosis 6. Medullary sponge Kidney 7. Idiopathic hypercalciuria Q4. What relevant investigation will you do? Ans. 1. Urine R/E (Urine pH is alkaline in renal tubular acidosis) 2. Serum parathyroid hormone (increased in hyperparathyroidism), serum calcium, phosphate, uric acid 3. IVU 4. computed tomography scan and magnetic resonance imaging 5. ultrasonography of kidney, ureter, bladder region 6. Chest X-ray: PA view (B/L hilar lymphadenopathy in sarcoidosis) 7. Acid load test (distal renal tubular acidosis) Images 82 Manual of Clinical Nephrology Q1. Describe the images. Ans. computed tomography renal angiogram showing accessory renal artery on both sides. Accessory renal arteries are common variant and are present in around 25% (range 2030%) and are bilateral in 10% of the population. Their identification is significant for surgical planning prior to living donor transplantation to reduce warm and cold ischaemic time.",
    "word_count": 581,
    "char_count": 3608,
    "sentence_count": 62,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 26,
      "total_chunks": 33,
      "position": "27/33",
      "content_type": "evidence",
      "content_type_confidence": 1,
      "medical_entities": [
        "calcium",
        "phosphate",
        "uric acid",
        "parathyroid hormone",
        "vitamin D",
        "hemodialysis",
        "catheter",
        "acidosis"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 27,
    "text": "Their identification is significant for surgical planning prior to living donor transplantation to reduce warm and cold ischaemic time. Accessory renal arteries occur bilaterally in 1015% of cases: Single renal artery arising from abdominal aorta (70%) Double renal arteries (20%) Triple renal arteries (2. 5%) Quadruple renal arteries (1%) Most commonly accessory renal arteries arise from the abdominal aorta and supply the inferior pole of the Kidney. Radiology and Imaging 83 Image Q1. Describe the image. Ans. This is a computed tomography-renal angiogram showing narrowing of the renal artery on the right side with accessory artery on the same side with shrunken Kidney. Q2. What are the indications of the above imaging? Ans. 1. To identify renal artery stenosis 2. To identify aneurysm of intra-renal arteries 3. To identify aberrant renal vessels 4. To identify renal mass 5. To identify renal parenchymal disease 6. To identify renal trauma Q3. What might be the clinical presentation? Ans. 1. Uncontrolled hypertension 2. Flash pulmonary Edema (particularly with bilateral disease) 3. Peripheral vascular disease of the lower limb 4. Renal impairment 5. Renal function deteriorates on ACE inhibitor or angiotensin receptor blocker. Q4. How will you manage this case? Ans. 1. Medical management: a. Control of hypertension (ACE inhibitor/angiotensin receptor blocker contraindicated in b/l renal artery stenosis) Renin inhibitor Diuretics Calcium channel blocker (amlodipine) 84 Manual of Clinical Nephrology b. Low dose aspirin: 75 magnesium/day c. Lipid lowering drugs: Statins 2. Surgical treatment: a. Angioplasty with placement of stent b. Auto-transplantation c. Renal ablation Image Q1. Describe the image. Ans. This is a computed tomography urogram showing partial duplex left Kidney with mild hydronephrosis. Q2. What is computed tomography urogram? Ans. A computerized tomography urogram is an imaging technique used to evaluate urinary tract including kidneys, ureters and urinary bladder. Q3. What are the uses and side effects? Ans. Uses: To diagnose Kidney stones bladder stones Ureteric stones Radiology and Imaging 85 Structural abnormalities Infection Tumor or cysts Side effects Flushing Nausea Itching Hives Pain near injection site Q4. What could be the presentation of the patient? Ans. May be asymptomatic May present with UTI May present with renal/ureteric stone Image Describe the X-ray. This is IVU showing paint brush appearance of renal medulla. Q1. What is the diagnosis? Ans. Medullary sponge Kidney (MSK) 86 Manual of Clinical Nephrology Q2. What may be the clinical presentation? Ans. May be asymptomatic May present with UTI May present with stone May present with hematuria Image Describe the X-ray. IVU showing splaying of the pelvicalyceal system (spider leg appearance) with hyperdense shadow (stone) on the left side (pelvis). Q1. What is your diagnosis? Ans. autosomal dominant polycystic kidney disease with stone (left) Radiology and Imaging 87 Image Describe the X-ray. IVU showing duplex pelvicalyceal system on the right side and triplex PCS on the left side. Q1. What may be the clinical presentation? Ans. May be asymptomatic May present with upper UTI May present with renal stone 88 Manual of Clinical Nephrology Image Describe the X-ray. IVU showing dilatation (beaded) of lower ureterbilateral ureterocele Q1. What may be the clinical presentation? Ans. May present with stone May present with hematuria May present with UTI May present with obstructive uropathy May be asymptomatic Radiology and Imaging 89 Image Q1. Discuss the tracing. Ans. diethylenetriamine pentaacetic acid scan renogram (diethylenetriamine pentaacetic acid) Q2. What are the phases? Ans. 1. Vascular or perfusion phase 2. Secretory or functional phase 3. Excretory phase Q3. Write a few indications. Ans. 1. Assessment of perfusion, filtration and drainage of Kidney. 2. Relative renal function. 3.",
    "word_count": 593,
    "char_count": 3933,
    "sentence_count": 85,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 27,
      "total_chunks": 33,
      "position": "28/33",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "renal function",
        "calcium",
        "magnesium",
        "diuretics",
        "statins",
        "edema"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 28,
    "text": "Write a few indications. Ans. 1. Assessment of perfusion, filtration and drainage of Kidney. 2. Relative renal function. 3. Dynamic renography gives useful information on degree of obstruction. 4. Renal artery stenosis. 90 Manual of Clinical Nephrology Images Q1. Describe the image. Ans. This is a computed tomography scan of kidney, ureter, bladder region showing multiple hypodense shadow. Q2. What is the diagnosis? Ans. autosomal dominant polycystic kidney disease Q3. What are the advantages of computed tomography? Ans. 1. More sensitive than ultrasound. 2. Can detect smaller cyst (0. 5 cm). 3. Not dependent on operator. Q4. How will the patient present? Ans. 1. Vague discomfort in loin or abdomen 2. Abdominal Pain due to cyst infection, cyst hemorrhage, nephrolithiasis, stretching of renal capsule and traction of vascular pedicle by large cyst, rarely tumor. 3. Hematuria 4. Urinary tract infectioncommonly E. coli, Kleibsiella, proteus 5. Hypertension (50% at presentation and nearly 90% when reached end-stage renal disease) 6. Nephrolithiasis 7. Renal failure 8. Cerebrovascular accident due to ruptured berry aneurysm 9. Renal cell carcinoma (rare) 10. Mitral valve prolapse, aortic aneurysm, colonic diverticula Q5. What are the vascular manifestations? Ans. 1. Berry aneurysm 2. Coronary artery aneurysm 3. Aortic root dilatation 4. Dissection of ascending aorta Radiology and Imaging 91 Q6. Mention poor prognostic factors. Ans. 1. More than 10 cysts at presentation 2. Severe hypertension at presentation 3. Renal failure at presentation Image Questions a. Describe the film. b. What is the diagnosis? c. What is the usual clinical presentation? d. What are the treatment options? Answer Key a. Renal angiogram b. Bilateral renal artery stenosis c. Refractory hypertension: Recurrent flash pulmonary Edema d. If the stenosis 75%, PTA or surgery 5 Transplant Work Up PREOPERATIVE WORK UP Confirm donor and recipient relationship by committee established for this purpose Informed About transplantation (surgery, post-transplant complication) Follow-up schedule (immunosuppressive drug) About total cost of transplant DONOR EVALUATION History and Examination A. History Hypertension Diabetes (including gestational) Infections Cancer (including skin lesions) Vascular disease Renal calculi Gout Urinary tract Family history of renal disease Medications (including NSAIDs, herbal medication, etc) Smoking Illicit and intravenous drug abuse Sexual history Vocation, sport interests 92 Transplant Work Up 93 Level of physical activity, exercise Psychiatric history, psychological factors Willingness to donate Relationship with recipient B. Examination Blood Hypertension Weight and height, body mass index (target body mass index 30) Joints, skin Cancer (including skin lesions, breast) Lymph nodes Vascular disease Heart lungs Abdomen Investigations A. Laboratory 1. Urine: a. Urine microscopy (Blood, Protein) b. Urine for culture 2. Twenty-four-hour Urine collection for a. Protein and b. Creatinine clearance 3. Complete Blood count with platelet count and differential count 4. Fasting Blood glucose and/or oral glucose tolerance test 5. Fasting lipid profile 6. Renal function tests: a. Serum Creatinine b. Blood urea, and c. Serum electrolytes 7. Liver function tests: a. Transaminase levels b. Serum albumin c. Serum bilirubin d. Prothombin time 8. Metabolic workup a. If previous renal stones b. Serum uric acid 94 Manual of Clinical Nephrology c. Serum calcium d. Serum phosphate e. Alkaline phosphatase f. 24 hours urinary calcium, uric acid 9. Coagulation studies to exclude bleeding diathesis a. Prothrombin time with INR (patient) b. Partial thromboplastin time (APTT) 10. Identify transmissible infectious disease: a. Viral screening: HBV and HCV HIV CMV EBV serology HSV b. Syphilis screening (RPR) c. TB screening (PPD) Rapid plasma reagin testing for tuberculosis (TB): TB skin testing, or QuanitFERON TB Gold B. Imaging 1. Electrocardiogram 2. Chest radiograph 3. ultrasonography 4. X-ray kidney, ureter, bladder region C. Immunologic Investigations 1. Blood group 2.",
    "word_count": 598,
    "char_count": 4104,
    "sentence_count": 85,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 28,
      "total_chunks": 33,
      "position": "29/33",
      "content_type": "treatment",
      "content_type_confidence": 3,
      "medical_entities": [
        "renal function",
        "renal failure",
        "end-stage renal disease",
        "creatinine",
        "urea",
        "calcium",
        "phosphate",
        "uric acid",
        "serum creatinine",
        "edema"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 29,
    "text": "Electrocardiogram 2. Chest radiograph 3. ultrasonography 4. X-ray kidney, ureter, bladder region C. Immunologic Investigations 1. Blood group 2. HLA typing 3. Cytotoxic crossmatch D. Age-appropriate Health Screening, Including Cancer Screening 1. Prostate-specific antigen (recommendations based on donor age and family history) 2. Gynecologic examination with Papanicolaous smear 3. Mammogram for women 40 years and older 4. Human chorionic gonadotropin quantitative pregnancy test in women younger than 55 years 5. Colonoscopy if 50 years or older 6. Echocardiography and cardiac stress testing as indicated 7. Pulmonary function studies and computed tomography scanning of the chest as indicated 8. Ambulatory Blood Hypertension 9. Serum Protein electrophoresis in prospective donors older than 60 years 10. Cystoscopy Transplant Work Up 95 E. Renal Imaging (According to Local Expertise) Computed tomographic angiography Magnetic resonance imaging angiography computed tomography urogram Glomerular estimated glomerular filtration rate determination by nuclear medicine test (diethylenetriamine pentaacetic acid scan renogram) RECIPIENT EVALUATION History and Examination Cause of renal failure and risk for recurrence Sensitization (transfusion, pregnancy, previous transplant) Past and current infections (TB, hepatitis, HIV) Immunization (especially hepatitis B) Malignancy Cardiovascular risks (smoking, hypertension, Diabetes) Pulmonary, gastrointestinal disease Genitourinary tract/disease Psychiatric, psychological history Surgical issues (weight, iliac vessels, abdomen, previous surgery) Laboratory and Radiologic Investigations A. Laboratory 1. Urine: a. Urine microscopy (Blood, Protein) b. Urine for culture 2. Twenty-four-hour Urine collection for a. Protein 3. Complete Blood count with platelet count and differential count 4. Fasting Blood glucose and/or oral glucose tolerance test 5. Fasting lipid profile 6. Renal function tests: a. Serum Creatinine b. Blood urea and c. Serum electrolytes 7. Liver function tests: a. Transaminase levels b. Serum albumin c. Serum bilirubin 8. Metabolic work up: Bone-related issues a. Serum uric acid b. Serum calcium 96 Manual of Clinical Nephrology c. Serum phosphate d. Alkaline phosphatase 9. Coagulation studies to exclude bleeding diathesis a. Prothrombin time with INR (patient) b. Partial thromboplastin time. (APTT) 10. Identify transmissible infectious disease: a. Viral screening: HBV HCV HIV CMV EBV serology HSV b. Syphilis screening (RPR) c. TB screening (PPD) Rapid plasma reagin testing for tuberculosis (TB): TB skin testing or QuanitFERON TB Gold B. Imaging 1. Electrocardiogram 2. Chest radiograph 3. ultrasonography 4. X-ray kidney, ureter, bladder region C. Immunologic Investigations 1. ABO Blood group and HLA typing 2. Screening for HLA antibodies and autoreactive antibodies 3. Crossmatching D. Age-appropriate Health Screening, Including Cancer Screening 1. Prostate-specific antigen (for men older than 50 to 60 years) 2. Gynecologic examination with Papanicolaous smear (sexually active women) 3. Mammogram (women older than 50 years or with family history of breast cancer) 4. Colonoscopy if 50 years or older 5. Echocardiography and cardiac stress testing as indicated Vaccination Against Hepatitis B, Inj. Hepa-B, IM (deltoid) 0, 1, 2 months Pneumococcal polysaccharide vaccine (Inj. Pneumovax23, IM, every 5 years) Meningococcal (Inj. Ingovax 0. 5 ml, IM: One time) Haemophilus influenzae (Inj. Influvax 15 microgram/0. 5 mlevery 1 year) Transplant Work Up 97 Influenzae virus type A Tetanus toxoid (Inj. Vaxitet 40 international unit/0. 5 ml0, 1, 6 months) Second Step Admit the recipient Do the due investigations. Referral to: Cardiology for both recipient and donor. Gastroenterology for endoscopy. Psychiatry for both recipient and donor. Medicolegal clearance including donorrecipient relationship Arrange transplant meetings. Do the following investigations of both donor and recipient CBC Urine RME Serum Creatinine and serum electrolytes RBS LFT (SGPT, SGOT, serum bilirubin) patient/APTT X-ray chest P/A view Admit the donor 2 days before surgery Inquiry about menstruation in case of female.",
    "word_count": 581,
    "char_count": 4192,
    "sentence_count": 57,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 29,
      "total_chunks": 33,
      "position": "30/33",
      "content_type": "dietary",
      "content_type_confidence": 2,
      "medical_entities": [
        "glomerular filtration rate",
        "renal function",
        "renal failure",
        "creatinine",
        "urea",
        "calcium",
        "phosphate",
        "uric acid",
        "serum creatinine",
        "screening"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 30,
    "text": "Send both donor and recipient to anesthesia department 1 day before surgery with recent follow-up investigation reports: hemoglobin% and platelet count Serum Creatinine, blood urea nitrogen and serum electrolytes RBS LFT (SGPT, SGOT, serum bilirubin) patient/APTT X-ray chest ECG and echo PREOPERATIVE FOLLOW-UP Pulse and blood pressure, temperature, Heart and lung, both donor and recipient 6 hourly. Target blood pressure for recipient is 140/90 but 160/100 PREOPERATIVE ORDER A. For Recipient (weight 60 kg) Nothing by mouth till further order from 10 pm of day before surgery. Please clean and shave the operative area from mid-chest to mid-thigh. 98 Manual of Clinical Nephrology Please take informed written consent. Please send the patient to surgery on the day of operation Tab. Midazolam 7. 5 magnesium (previous night before the day of surgery) 1 tab at 10 pm. Tab. Duralax 2 Tab at night Fleet enema at night. Cap. Tacrolimus 0. 15 magnesium/kg bw in 2 divided doses (start from 1 day before surgery). On operative day give total dose at 5: 30 am with minimum Water. OR Cap. Cyclosporine: 8 magnesium/kg bw in 2 divided doses (start 1 day before surgery). On operative day give total dose at 5: 30 am with minimum Water. Tab. MMF 500 magnesium 1 and 1/2 0 1 and 1/2 (Start 1 day before surgery) On operative day take 3 tab (1500 magnesium) at 5: 30 am. Hemodialysis 4 hours hemodialysis on day before surgery at 2: 00 pm Post-Dialysis advice CBC, serum Creatinine and serum electrolytes. B. For Donor Nothing per oral from 10 pm before day of surgery. Please clean and shave the operative area from mid-chest to mid-thigh. Please take informed written consent. Please send the patient to OT on the day of operation. Inf. 0. 9% NaCl IV 2 L 40 drops/min from preoperative night at 6 pm (cannula by 18 G on left hand) Tab. Midazolam 7. 5 magnesium 1 tab at 10 pm. Tab. Duralax 2 tab at night Fleet enema on preoperative night. INQUIRY BEFORE OT About bowel movement of both donor and recipient. Morning blood pressure of both donor and recipient. Morning dose immunosuppressive drug. Transplant Work Up 99 OPERATION NOTE 1. Primary diagnosis 2. Donor type 3. Tissue typing 4. Crossmatching 5. Warm ischemic time 6. Cold ischemic time 7. CMV status both donor and recipient 8. Induction a. Basiliximab 20 magnesium at OT (2 hours prior to transplant surgery) 9. Intraoperative period POSTOPERATIVE ORDER Nothing by mouth till further order from 10 pm of day before surgery Fluid: According to protocol. Inj. Methylprednisolone 500 magnesium N/S 200 ml IV daily for 3 days (1st dose at OT). Inj. Ceftriaxone 1 gm IV daily Inj. Omeprazole 40 magnesium IV 12 hourly Inj. Pathedine 100 with prochlorperazine injection. 3/4 (75 magnesium) IM 8 hourly Inj. Vergon 1 amp slowly IV given before giving Pathedine. Anadol suppository 100 magnesium (SOS) Measure pulse, blood pressure, temperature, R/R, SpO initially half hourly, then hourly. 2 Maintain I/O chart. On 1st Postoperative Day and Onward: Add Cap. Tacrolimus (0. 15 magnesium/kg BW)/ Tab. Cyclosporine (8 magnesium/kg BW). On 1st postoperative day take total dose at 9: 00 pm From 2nd POD, 2 divided doses. Tab. MMF 500 magnesium/Tab. Myfotic 360 magnesium/Azathioprine 2 magnesium/kg/day On 1st postoperative day, take 3 tab (1500 magnesium) at 9: 30 pm. 1 and 1/2 0 1 and 1/2 (start from 2nd POD) On 2nd POD Sips of Water, then liquid diet (if bowel sound present) Tab. Prednisolone 0. 5 magnesium/kg/day. 100 Manual of Clinical Nephrology Table 5.",
    "word_count": 590,
    "char_count": 3510,
    "sentence_count": 67,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 30,
      "total_chunks": 33,
      "position": "31/33",
      "content_type": "dietary",
      "content_type_confidence": 2,
      "medical_entities": [
        "creatinine",
        "urea",
        "magnesium",
        "hemoglobin",
        "blood urea nitrogen",
        "serum creatinine",
        "diet",
        "dialysis",
        "hemodialysis"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 31,
    "text": "Prednisolone 0. 5 magnesium/kg/day. 100 Manual of Clinical Nephrology Table 5. 1: Risk of CMV according to serological status Donor CMV status Recipient CMV status Risk ve ve Low ve ve High ve ve Medium ve ve Medium Either donor and/or ve and treatment with depleting High recipient CMV antibody Table 5. 2: Dosing of Valganciclovir in renal impairment Creatinine clearance Induction of Valcyte tablets Maintenance/prevention (milliliters per minute) dose of Valcyte tablets 60 900 magnesium (2 tablets) twice daily 900 magnesium (2 tablets) once daily 4059 450 magnesium (1 tablet) twice daily 450 magnesium (1 tablet) once daily 2539 450 magnesium (1 tablet) once daily 450 magnesium (1 tablet) every 2 days 1024 450 magnesium (1 tablet) every 2 days 450 magnesium (1 tablet) twice weekly 10 Not recommended Not recommended On 4th POD Inj. Basiliximab 20 magnesium IV slowly over 10 min On 8th POD Tab. Valganciclovir (when serum Creatinine becomes stable): 450 magnesium OD Tab. Cotrimoxazole: 480 magnesium Send Blood for trough/C2 level of CNI.",
    "word_count": 168,
    "char_count": 1051,
    "sentence_count": 8,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 31,
      "total_chunks": 33,
      "position": "32/33",
      "content_type": "recommendation",
      "content_type_confidence": 1,
      "medical_entities": [
        "creatinine",
        "magnesium",
        "serum creatinine"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 32,
    "text": "Valganciclovir (when serum Creatinine becomes stable): 450 magnesium OD Tab. Cotrimoxazole: 480 magnesium Send Blood for trough/C2 level of CNI. Index A Compartment A 76 Compartment B 76 Abdominal 15, 25, 26, 42, 52, 58, 59, 70, 82, 90 Continuous ambulatory peritoneal Acidbase disorder 61 Dialysis (continuous ambulatory peritoneal dialysis) 13 Acne 1, 2, 4, 51 catheter 73 Addisons disease 2 computed tomography urogram 84 Amputation 16, 18 computed tomography-guided FNAC 44 Anaemia 28 Cushings Angioedema 2 disease 3 Angioplasty 18, 24, 84 syndrome 1, 3 Anticoagulation 20 Cytomegalovirus 11 Anti-filarial drugs 42 Cytotoxic crossmatch 94 ARA criteria 29 Area 17, 18, 51, 54, 59, 72, 78, 97, 98 D Arrhythmia 45, 63 Arteriovenous fistula 4, 68 DDAVP 62 Arthralgia 26, 27, 61 D-dimer 19 Auscultation 13, 21 Delayed graft function 7 A-V fistula 4, 49, 57 Depression 2 Device damage 68 B Diabetes mellitus 12 Diabetic Backache 2 foot 17 Baker cyst 19 ulcer 18 Biofilm formation 68 Diarrhea 5 BK (polyoma) virus 11 Diffuse parenchymal lung disease (DPLD) 2 Bleeding disorder 68 Dislocation and malposition 68 Blood Distal renal tubular acidosis 81 group 94 Donor evaluation 92 Hypertension 1 Drowsiness 50 Glucose 3 Drug rash 25 body mass index 93 Duplex pelvicalyceal system 87 Bone Dysfunction 68 marrow suppression 5 mass density 3 E Pain 1 Buffalo hump 1 EBV serology 96 Buzz 21 Edema 4 Electron beam 67 C Ethylene oxide gas 67 Callus 18 F Cardiac arrhythmia 63 Cataract 2 Fibrin sheet formation 68 Central venous stenosis 68 Foot 17 Chronic alcoholism 2 ulcer 16 Chyluria 42 Fungal infection 4 chronic kidney disease G 5D patient 50 stage-4 57 -irradiation 67 stage-5 patient 49 Gait abnormality 51 Cloudy effluent 71 General management 20 CNI 5 GI Cognitive dysfunction 51 bleeding 46 Cold ischemia 6 perforation 46 101 102 Manual of Clinical Nephrology Gitelman syndrome 45 M Glomerulonephritis 2 Maintenance therapy 32 Gout 92 Managing NODAT 12 Gum hypertrophy 4 Medullary sponge Kidney 81 Micturition 37 H Monitoring immunosuppressive medications 9 Headache 50 Monitoring Kidney allograft function 10 Hemodiafiltration 68 Monoclonal gammopathy 55 Hemodialysis fluid 76 Mood disturbance 2 Henoch-Schnlein purpura (HSP) 25, 46 Moon face 1 Hirsutism 2, 4 mTOR inhibitors 5 Histology 26 Multiple erythematous purpuric rash 46 History of contact with active PTB patient 44 Multiple myeloma 55 HLA typing 94 Myxedema 2 Hollow fibers dialyzer 66 N Horseshoe Kidney 58 Hyperglycemia 5 Nausea 5 Hyperkalemia 63 Nephrocalcinosis 81 Hyperlipidemia 5 Nephrotic syndrome 2 Hyperparathyroidism 81 Neuropathic 17 Hypertension 2, 12 Night sweat 44 Hypocalcaemia 63 Nocturia 37 Hypokalemia 3 NODAT 5 NSAIDs 92 I O Idiopathic hypercalciuria 81 Illicit and intravenous drug abuse 92 OSPE station 37 Immunosuppressive drugs 5 Osteoporosis 1, 2 Indomethacin 45 Oxybutynin 62 Induction therapy 8 P Insomnia 2 Inspection 13, 21 Paint brush appearance 85 Instrument and specimen 65 Palpation 13, 21 Intussusception 46 Pancreatitis 5 Irritability 2 Papanicolaous smear 94 Ischemic 17 Parallel plates dialyzer 66 ITP 25 Partial thromboplastin time 94 IVU (intravenous urogram) 79 Patients education 18 Pemphigus vulgaris 2 potassium Percussion 13 Permcath Dialysis catheter 69 Kidney Disease: Improving Global Outcomes guideline 27 Plasmapheresis 68 Kidney allograft biopsy 11 Pneumonia 5 kidney, ureter, bladder region 48, 80 Polycystic Kidney disease 35 Ponticelli regimen 61 L Post-transplant Labial salivary gland biopsy 61 antimicrobial prophylaxis 7 Large hematoma 68 lymphoproliferative disease (PTLD) 6 Latent tetany 45 Prognosis 26 Leukopenia 5 Prothrombin time with INR 94 Local infection 68 Pruritus, bone Pain 64 PTFE graft 69 Lupus nephritis treatment 31 Puffy face 1 class I LN 31 Pulse 17 class II LN 31 class III LN 31, 32 R class IV LN 31, 32 class V LN 32 Radiology and imaging 79 class VI LN 32 Rash 26 Index 103 Reflex 17 T Renal Tacrolimus 5 biopsy 60 TB screening (PPD) 96 calculi 92 Thrill 21 function test 60 Thrombocytopenia 5 involvement 26 Thrombosis 23, 68 transplantation 5 of AV fistula and graft 23 Rheumatoid arthritis 2 Thrombotic thrombocytopenic purpura (TTP) 25 Rule of sixes 24 Transplant work up 92 Treatment of S acute rejection 9 Sarcoidosis 81 chronic allograft injury 10 Sclerotherapy 42 Tremor 4 Sensation 17 Truncal obesity 2 Septicemia 25 Tuberculin test 44 Serum Types of membranes 67 ACTH 3 modified cellulose 67 Creatinine 10 regenerated cellulose 67 Protein electrophoresis (SPEP) 55 synthetic 67 Sestamibi scan 48 SIADH 61 U Signs of clotting of extracorporeal circuit 75 Ulcer 17 Sjgrens syndrome 61 Urgent hemodialysis 68 Skin malignancy 4 Urinalysis 60 SLE 25 Urinary tract 92 Smoking 44 Urinary tract infection 12 Spider leg appearance 86 Urine Protein electrophoresis (UPE) 55 Spironolactone 45 Urine Glucose 1 Sputum for Uroflowmetry 37, 38 AFB staining and AFB culture 44 cytology 44 V GeneXpert for MTB 44 gram staining 44 Vascular disease 92 Steam autoclaving 67 Venography 19 Steroid 2 Viral warts 4 Strategies to reduce drug costs 9 Vomiting 5, 50 Striae 1, 2 W Structured clinical assessment (SCA) 37 Surgical emphysema 2 Warm ischemia 6 Syphilis screening (RPR) 96 Weight loss 44",
    "word_count": 836,
    "char_count": 5227,
    "sentence_count": 3,
    "metadata": {
      "source_file": "manual-of-clinical-nephrology-first-edition_compress.pdf",
      "extraction_date": "2025-12-31T14:23:50.330223",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2020",
      "keywords": [
        "renal",
        "nephrology"
      ],
      "chunk_index": 32,
      "total_chunks": 33,
      "position": "33/33",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "nephritis",
        "creatinine",
        "potassium",
        "magnesium",
        "serum creatinine",
        "dialysis",
        "hemodialysis",
        "peritoneal dialysis",
        "fistula"
      ],
      "entity_count": 10
    }
  }
]